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1. INTRODUCTION 
 
1.1. PHARMACEUTICAL CARE AND PROFESSIONAL DEVELOPMENT 
 
Pharmaceutical Care was defined by Hepler and Strand in 1990 as the responsible 
provision of drug therapy for the purpose of achieving definite outcomes that improve 
patient’s quality of life [1]. Providing pharmaceutical care was soon found to be 
beneficial to the patient, the society and other health care professions and was 
promoted among pharmacists in Germany a few years later by Derendorf and 
others [2]. Along with the professional changes the World Health Organization 
(WHO) and the International Pharmaceutical Federation (FIP) have published a 
handbook on developing pharmacy practice with a strong focus on patient care in 
2006, which was used as a blueprint for many countries worldwide [3]. The definition 
of pharmaceutical care was updated by the Pharmaceutical Care Network Europe in 
2013 as [4]:  
 
“Pharmaceutical Care is the pharmacist’s contribution to the care of individuals in 
order to optimize medicines use and improve health outcomes” 
 
New tools like Medication Review and Medication Management with its underlying 
clinical sciences are new services to serve the patient. They might as well have a 
strong impact on positioning the pharmaceutical profession in a future healthcare 
system, as the pharmacist is involved as an active player in therapy and is enhancing 
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the therapeutic outcomes. Evolving and transforming pharmacy as a science and 
profession faces several challenges, as described by van Mil at al. in a review in 
2004 [5]. Ten years later, in 2014, German pharmacists voted for a new orientation 
towards patient services [6]. Providing the profession with basic research results was 
the driving force behind these elaborations and this dissertation. 
 
1.1.1. RESEARCH IN PHARMACEUTICAL CARE 
 
During the last two and a half decades several pharmaceutical care studies were 
conducted to demonstrate the effects of pharmaceutical interventions on outcomes 
like adherence, costs, laboratory and surrogate parameters or other definite clinical 
endpoints [7–10].  
Initially, many pharmaceutical care studies focused on patient education provided by 
a pharmacist. Patient education by pharmacists increased the quality of life of 
patients with diabetes [11]. The DIADEMA-study reached a significant change in 
glycated hemoglobin A1c (HbA1c) in type-1 diabetic patients after 6 months of 
motivational interviews by community pharmacists [12]. Patient education by 
pharmacists within the GLICEMIA program led to a significant reduction in the 
FINDRISC score [13], a type-2 diabetes mellitus risk score [14]. Benefits of 
pharmaceutical care have been reported in breast and ovarian cancer with a focus 
on patient counseling [15] as well as in palliative care by Needham et al. [16]. Patient 
education of pharmacists was effective in optimizing the handling of asthma-
inhalation devices [17, 18]. In a recent systematic review Jalal et al. found that 
 1. Introduction / p.10 
 
 
pharmaceutical patient education has a good level of evidence to be beneficial on 
cardiovascular outcomes in increasing medication adherence [19]. 
Increasing medication adherence is another typical pharmaceutical care activity that 
can be affected by pharmacists [20]. A meta-analysis by Carter et al. showed a 
reduction in systolic blood pressure by pharmaceutical interventions in the hospital 
and community setting of 7.76 respectively 9.31 mm Hg [21].  
Other examples of pharmaceutical care services are screening for interactions or use 
of inappropriate drugs [22–25] searching for prescription errors or any kind of drug-
related problem (DRP) [26–28], supporting disease screenings or to perform a 
Medication Review or Medication Management. Cai et al. concluded that 
pharmaceutical interventions have a positive impact on adherence, blood pressure or 
lipid management but failed to reduce mortality, cardiac events or hospitalization in a 
systematic review on coronary heart disease [29]. A systematic Cochrane review in 
2010 tried to evaluate the benefits of pharmaceutical patient services but complained 
that current studies are too heterogeneous to be pooled and that pharmaceutical 
services can hardly be compared to care services, delivered by other health care 
professionals [30]. In summary, many pharmaceutical care studies have been 
published in several specific settings and the benefits could be demonstrated, but the 
heterogeneity of the studies makes it difficult to draw a final evidence-based 
conclusion. 
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1.2. MEDICATION REVIEW AND MEDICATION MANAGEMENT 
 
Medication Therapy Management (MTM) as a new tool in pharmaceutical care was 
implemented first in the Medicare Prescription Drug, Improvement, and 
Modernization Act of the United States of America, where Part D regulates access to 
a Medication Therapy Management for certain patients [31]. Medication Therapy 
Management or Medication Management as well as Medication Review are used 
synonymously in many countries and are current international trends with the 
potential to have a profound impact on patient outcomes and on pharmaceutical 
practice. Both approaches are based on a patient-oriented view on medication safety 
and pharmacotherapy and require clinical knowledge as well as clinical experience. A 
Medication Review was defined by the Pharmaceutical Care Network Europe 
(PCNE) [32]. Amendments of the current definition were suggested at the PCNE 
working symposium in Hillerød in 2016 and are published as [33]:  
 
“Medication review is a structured evaluation of patients’ medicines with the aim of 
optimizing medicine use and improving health outcomes. This entails detecting drug- 
related problems and recommending interventions” 
 
In the United Kingdom a Medication Review is called Medicines Use Review by the 
Royal Pharmaceutical Society and the National Health Service whereas the 
American College of Clinical Pharmacy (ACCP) favors the terms Comprehensive 
Medication Management (CMM) and Collaborative Drug Therapy Management 
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(CDTM) [34, 35].  A Medication Review as a pharmaceutical service is called 
“Polymedikations-Check” in Switzerland [36]. In Australia, the Australian Association 
of Consultant Pharmacy (AACP) established the "Home Medicines Review (HMR)" 
[37]. In a Medication Management pharmacotherapy and medication safety are 
considered. Aspects for an assessment are potential contraindications, dosage errors, 
wrong dosage intervals, handling problems, non-adherence, potential therapeutic or 
drug doublets, prescribed drugs without an indication or detected indications without 
a drug. In addition to increasing medication safety, therapeutic as well as patient 
goals should be expressed and options to reach these goals should be suggested 
and wherever possible implemented. In a so called "Brown Bag Review" the drug use 
of the patient (supplied to the pharmacist in a “brown bag”) is compared to the 
medication plan of the prescriber and discrepancies are analyzed. Medication 
Reconciliation is regarded as a typical first step in a Medication Review. 
Discrepancies in dosages are examined. A patient interview, data collection and an 
analysis and assessment of the therapy is the second step, followed by 
documentation and further action. The implementation of a Medication Review and a 
Medication Management in community pharmacies as well as on the ward, is based 
on expanded skills in clinical pharmacy and pharmacotherapy, all efforts should be 
patient-oriented. Medication Review is the preferred wording by the PCNE. A 
Medication Review is the structured approach to assess a patient’s drug therapy. The 
PCNE defines four types of Medication Reviews based on the origin of the data 
sources (table 1) [38]: 
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Tab. 1: Different types of a Medication Review, based on the 
data sources, according to the PCNE definition [38] 
Data source Type 1 Type 2A Type 2B Type 3 
pharmacy record yes yes yes yes 
patient information no yes no yes 
medical records/lab data no no yes yes 
 
These 3 types of Medication Review were adopted by the Federal Union of German 
Associations of Pharmacists (Bundesvereinigung deutscher Apothekerverbände, 
ABDA), which calls a Medication Review “Medikationsanalyse” in German language. 
Medication Management or Medication Therapy Management is a term mainly used 
in the USA in an equivalent way to Medication Review [31]. In German language the 
term Medication Management, translated as "Medikationsmanagement", was defined 
by the German Pharmaceutical Society (DPhG) and was developed as longitudinal 
and interprofessional patient care by the ABDA in 2014 [39, 40]. According to the 
ABDA definition, Medication Management (Medikationsmanagement) requires further 
action after a Medication Review (Medikationsanalyse) is done, which could be a 
repeated review, the initiation of therapeutic changes, or any kind of activity that is 
undertaken to solve detected DRPs. Interprofessional cooperation is another crucial 
aspect mentioned by the ABDA definition of "Medikationsmanagement". As 
pharmacists in Germany cannot change any medication without a prescriber, a 
physician needs to be involved in most interventions. Cooperation with other health 
care providers (like home care experts or nurses) can be required as well and is 
another example for interprofessional collaboration.  
 1. Introduction / p.14 
 
 
Medication Management services gradually have evolved from patient education and 
medication-safety aspects to therapy consultations [41]. Pharmacists tend to play a 
more active role in several settings nowadays. A Medication Management is 
available for eligible patients in the USA, the UK, Switzerland, Poland, Slowenia and 
many other countries [42]. In the USA Medication Management is offered as the most 
prevalent patient oriented service by 60% of the pharmacists, according to the 
national pharmacist workforce survey 2014 by the American Association of Colleges 
of Pharmacy (AACP) [43]. 
Case reports in the Medizinische Monatsschrift für Pharmazeuten and in the 
Deutsche Apotheker Zeitung demonstrated Medication Management during the last 
decade in Germany [44–47]. In 2013 a Medication Management was defined by the 
“Apothekenbetriebsordnung” in §1a and §3. A Medication Management in Germany 
has been introduced as a pharmaceutical service, which has to be done personally 
by a pharmacist. Along with the omitting implementation in standard care, research 
on Medication Management in Germany is still scarce.  
 
1.2.1. RESEARCH IN MEDICATION MANAGEMENT 
 
During the past two decades, several remarkable studies and reviews on Medication 
Review and Medication Management have been conducted. In an early study by 
Hanlon et al. in 1996 the prescription of inappropriate drugs declined by 24% (versus 
6% in the control group) by Medication Management (p=0.0002) [48]. Machado et al. 
found in a review that patient education and Medication Management can 
significantly reduce LDL-cholesterol by up to 32.6 mg/dl (p < 0.001) [49]. Chisholm-
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Burns et al. reviewed significant improvements by a Medication Management 
focusing on LDL-cholesterol, blood pressure, HbA1c and the reduction of adverse 
drug events (p<0.05) [50]. Planas et al. found provided Medication Managements 
helpful in reducing blood pressure by 17.32 mm Hg in a small study in 2003 [51]. 
Ramalho de Oliveira et al. determined in a large review article in 2010, based on 
Medicare Part-D data, that Medication Management programs have shown to 
improve clinical outcomes and to reduce costs [52]. A systematic review for the 
Cochrane Database on the effects of a Medication Management for elderly patients 
in care homes stated that the considered studies were too different in design and 
baselines to draw a final conclusion [53]. A meta-analysis came to the result that 
there is little evidence to show that Medication Management interventions can 
improve health outcomes, whereas they might help to solve some drug-related 
problems, including nonadherence, and might lower health-care costs [54]. Further 
studies are still desired and there is a strong demand to add evidence to the positive 
outcomes that could be reached by pharmacists’ interventions for the patient. The 
efficacy of a Medication Management is particularly depending on the setting and 
grade of collaboration of the health care provider team. The acceptance of the 
pharmacist`s recommendation by the physician (and other health care providers) is 
another crucial point in providing patient-oriented services. Obviously, an intense 
pharmaceutical work-up cannot lead to any improvement, if the interventions do not 
reach the patient. Interprofessional collaboration as a potential confounder hence 
needs to be addressed in any Medication Management. The acceptance of the 
suggestions provided by pharmacists through a Medication Management was 
analyzed in 2005 by Doucette et al., who implemented a Medication Management in 
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community pharmacies and followed the outcomes of the interventions. Drug-related 
problems were addressed and almost 50% of the interventions were accepted by the 
physicians in charge [55]. A smaller study in community pharmacies rated the 
acceptance of pharmaceutical suggestions between 42 and 60% [56]. Professional 
collaboration and acceptance are the bottleneck in performance of any Medication 
Management. 
 
1.2.2. ENDPOINTS IN MEDICATION MANAGEMENT STUDIES 
 
Several endpoints have been used in previous studies to evaluate the effects of a 
Medication Management on drug therapy. Implicit or explicit endpoints can be 
chosen to assess the efficacy of a Medication Management. Explicit parameters are 
single laboratory data or vital signs, which can be obtained objectively [57]. Complex 
changes induced by a Medication Management, like the quality of therapy, can be 
formulated much better by implicit scales that consist of more than just one 
parameter and need further analysis to be done. Changes in the quality of therapy, 
DRP, quality of life or adherence need further evaluation to be rated and thus are 
regarded as implicit parameters. 
 
1.2.3. QUALITY OF THERAPY  
 
A meaningful approach to evaluate the effects of a Medication Management is to 
measure the quality of therapy. The Health Plan Employer Data and Information Set, 
the so called HEDIS goals are a tool to measure, rate and score changes in 
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medication [58]. HEDIS goals consist of surrogate endpoints and vital-sign goals, to 
meet targets in HbA1c, LDL-cholesterol or blood pressure. HEDIS goals were the 
primary endpoint in a landmark study that was among the first studies to show a 
defined benefit from a Medication Management under controlled trial terms [59, 60]. 
The Medication Appropriateness Index (MAI), developed by Hanlon et al. in 1992 is 
another tool to rate the quality of therapy [61]. It has been evaluated to correspond to 
hospital admissions and for the prediction of adverse drug events and was modified 
by Samsa et al. as a weighted measure for the quality of therapy in pharmaceutical 
care [62–64]. The MAI consists of 10 questions per drug to identify potential 
medication safety or therapeutic issues. Higher MAI scores indicate a low quality of 
drug therapy. A more detailed explanation of the MAI can be found in the methods 
chapter (3.1.5.). A Cochrane review in 2011 revealed that the majority of studies of 
high quality rely on the MAI, seven out of eleven randomized controlled trials were 
based on the MAI as the primary endpoint [65]. The MAI has been tested and 
evaluated in various settings [66–69]. An article by Hanlon and Schmader in 2013 
compared all RCTs that used the MAI and competing scores during the last 20 years 
[70]. They came to the conclusion that the MAI is “best at detecting prescribing 
improvement over time” but “most time consuming to apply” [70].  Besides for 
patients with polymedication and with widespread diseases the MAI was successfully 
used in special indications like in psychiatry in a study by Wolf et al. in 2015, even 
though the baseline MAI of 2.3 was extremely low, indicating an already high quality 
of drug therapy at baseline [71]. A higher absolute reduction in the MAI obviously 
could be reached with a higher baseline MAI. Castelino et al. reached a 9.3 MAI 
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reduction in patients with a MAI of 18.6 at baseline, indicating a low quality of therapy 
at study entry [72]. 
 
1.2.4. MEDICATION SAFETY AND DRUG-RELATED PROBLEMS 
 
Another aspect of a Medication Management is to address medication safety, which 
seamlessly overlaps with the quality of therapy. DRP classification systems usually 
cover both aspects. Various systems have been developed during the past two 
decades. Van Mil et al. identified 14 different systems already in 2004 [73].The 
probably first approach on classification was developed by Hepler and Strand. They 
defined 8 categories of DRPs, which were initially used at the University of Florida in 
teaching and practice and have been published later in a statement by the American 
Society of Health-System Pharmacists (ASHP) in 1993 [74]. DRP categories 
according to Hepler and Strand are: 
1. Untreated indications 
2. Inproper drug selection 
3. Subtherapeutic dosage 
4. Failure to receive medication 
5. Overdosage 
6. Adverse drug reactions 
7. Drug interactions 
8. Medication use without indication 
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The Hepler and Strand criteria are still used in the USA to date. Several alternative 
classification systems were developed with regard to the specific setting and use. 
Classification systems for use in a community pharmacy show fewer categories 
compared to the hospital setting. The Westerlund classification is an example of a 
practical structured system [75, 76]. It consists of 11 kinds of DRPs: uncertainty 
about the aim of the drug, insufficient or no therapeutic effect (therapy failure), 
underuse of drug, overuse of drug, drug duplication, adverse reaction/side effect, 
interaction, contraindication, inappropriate time for drug intake/wrong dosage interval, 
practical problems and other DRPs. 
The classification system of the PCNE is in contrast to the Westerlund system very 
detailed. The current version used during these studies was 6.2 [77]. Version 7 was 
published in 2016 [78]. The PCNE classification is structured into problems, causes, 
interventions and outcomes with several domains and subdomains. It might be most 
widely established in recent research as it has been tested for validity and 
reproducibility [79]. The Swiss Society of Public Health Administration and Hospital 
Pharmacists (GSASA) developed an evolution, with a focus on easy handling [80]. 
The DOCUMENT classification has a similar approach as the GSASA [81]. Several 
other classification systems were developed with regard to specific settings. In 
various settings significant effects of pharmaceutical interventions in reducing DRPs 
could be demonstrated [55], [82–85]. 
A more confined approach to increase medication safety is a focus on the use of 
potential inappropriate medications (PIM) for the elderly. Gustafsson et al. reached a 
significant reduction of PIM through a pharmaceutical intervention in Swedish nursing 
homes [86]. Further insight into the approaches of PIM reduction was provided by a 
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review article and a detailed description on their implementation, which became a 
natural part of any Medication Management in elderly patients [87, 88]. 
 
1.2.5. DRUG-DRUG INTERACTIONS 
 
Drug-drug interactions, as one category of DRPs can be identified with numerous 
software programs. In the meantime, several attempts have been undertaken to 
compare these tools. There are some differences in severity staging or in the number 
of less relevant interactions. Furthermore, international tools can hardly be compared, 
due to a difference in nationally registered drugs, but most studied databases provide 
a helpful assistance in detecting interactions [89]. Roblek et al. in contrast found little 
accordance between international databases with an overlap as low as 11% in some 
cases [90]. In these comparative studies, less attention is paid on the clinical 
relevance of the interactions but rather on the mere number of interactions. The 
relevance of interactions can hardly be defined or classified but rather depends on 
clinical experience and the specific setting. Furthermore, drug-drug interaction 
software does not take interactions of more than 2 drugs into account. An important 
aspect is to avoid a so called “alert fatigue” with too many reported interactions to the 
prescriber [91].  
 
1.2.6. QUALITY OF LIFE 
 
A patient-oriented approach to measure outcomes of a Medication Management is to 
study the quality of life, measured by the SF12 or SF36 score [92], by the WHO-5 
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well being index or various other scores [93]. Changes in the quality of life by a 
Medication Management were challenged by several studies. Surprisingly, results 
are controversy [94, 95]. This might be due to the short observation period in most 
pharmaceutical care studies or to the limited relevance of drug therapy to the quality 
of life.  
 
1.2.7. COMPLIANCE AND ADHERENCE 
 
Adherence is defined by the WHO as "the extent to which a person’s behaviour – 
taking medication, following a diet, and/or executing lifestyle changes, corresponds 
with agreed recommendations from a health care provider" [96]. The patient`s 
agreement is a crucial aspect of the definition and the main distinction between the 
terms adherence and compliance [97, 98]. Medical societies like the American Heart 
Association (AHA) and the American Diabetes Association (ADA) recognize the 
relevance of non-adherence on therapeutic outcomes in their standards and 
guidelines [99, 100]. The AHA emphasizes the importance to evaluate measurement 
of adherence and establish standards. A circulation report in 2009 helped to define 
adherence problems for cardiovascular indications [100]. Improvement in compliance 
and adherence is an original task for pharmacists [101]. A standard method to 
improve adherence is the motivational interview. Pharmacists educate the patients 
about drugs under various aspects and help to understand the drugs, their 
indications, its effects and its handling. Several studies could show a positive 
outcome of a pharmaceutical intervention on adherence in diverse settings, 
underlining the importance of a pharmacist in the therapeutic team [102–105]. 
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1.2.8. COSTS 
 
Reducing costs might be a major point of interest for health care stakeholders like 
national, public and private health insurances. Costs could be regarded as drug costs, 
the wider field of therapeutic costs, health costs (covering any type of intervention) or 
even overall costs for the society, including loss of labor days. Regarding a 
Medication Management only few studies on its cost efficacy are available. Costs in 
asthma therapy dropped by pharmacists’ interventions due to a decline in emergency 
department visits [106]. A study by Stuart et al. on Medicare Part D expenses 
concluded that low adherence leads to additional costs between 49 and 840 $ per 
month in patients with diabetes, which likely could be reduced by a Medication 
Management [107]. As falls account for tremendous costs [108], a reasonable target 
to measure savings could be the reduction of falls by watching out for potential 
inadequate medication (PIMs) in the elderly. In this context, eliminating 
anticholinergic drugs wherever possible or reducing drastic blood pressure lowering 
are typical pharmaceutical care activities. Ramalho de Oliveira et al. analyzed the 
data of 10 years of Medicare Part D services in Medication Management in the USA 
and reported a saving of 86 $ per encounter with a pharmacist [52]. The 
consideration on costs would need to take the costs of the intervention into account 
comprising of the reimbursement of all involved health care providers. In the study by 
Ramalho de Oliveira et al. these costs were calculated with 67 $ per encounter, 
which results in a 19 $ saving for the health insurance [52]. Isetts et al. found that 
total annual health expenditures decreased from 11965 $ to 8197 $ per patient and 
calculated that the costs of a Medication Management in relation to the savings is 
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1:12 [60]. Wittayanukorn et al. conducted an analysis in patients with cardiovascular 
diseases with significantly lower total, pharmacy and medical health care 
expenditures in the Medication Management group compared to the control group 
[109].  
 
1.2.9. PATIENT SELECTION IN MEDICATION MANAGEMENT 
 
Patient selection for a Medication Review or a Medication Management is done 
mainly by the pharmacist (“pull referral”) or by the health insurances (“push referral”) 
[41]. In Switzerland and Australia, a medication review is typically initiated by the 
pharmacist, whenever DRPs are detected [110–112]. The Australian Residential 
Medication Management Review on the other hand needs to be initiated by a 
physician for reimbursement [113, 114]. In the United States (US), patients are 
referred to a Medication Management mainly through insurance companies [115]. 
Medication Management programs in the US vary and health expenditure might be 
an unpretentious criterion for patient selection [115]. In Great Britain patients are 
eligible for a Medicines Use Review if they have been prescribed two or more 
medicines and are regular users of the pharmacy [116]. The variety of selection 
criteria indicates that no evidence-based criteria have been assessed so far. 
Rosenthal et al. published an article describing the Medication Regimen Complexity 
Index (MRCI) as a potential criterion to identify patients for Medication Management 
[117, 118]. The study didn`t test for any correlation between the outcomes though 
and doesn`t provide new insights. 
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1.3. IDENTIFYING HIGH-RISK GROUPS 
 
As pharmacists worldwide are implementing pharmaceutical care services like 
Medication Reviews and Medication Management, they might be facing limited 
capabilities in time and manpower. As a consequence of a shortage in manpower, 
pharmacists might want to focus on certain patient populations to identify those, who 
carry the highest benefit from a Medication Management, as long as this service 
cannot be offered to every eligible patient. Limited resources should be used in the 
most effective and appropriate way. In a report of the chief pharmacist Giberson et al. 
to the U.S. Surgeon General, several examples on how medication services are 
restricted to the population in the US are mentioned [119]. At that time, in 2011, only 
12% of all eligible patients in the US had access to a Medication Management. 
Health insurance companies restricted patients from these pharmaceutical services 
as they were limiting it to the elderly, handicapped or socially deprived patients. The 
criteria for these limitations do not seem to be based on ethics or evidence but rather 
on financial or arbitrary considerations. A consequent approach by some health 
insurance companies in the USA is to offer Medication Management services only to 
patients consuming drugs of more than 3000 US-Dollars per year [120]. A change to 
a diagnosis-related access is suggested by US pharmacists as a better criterion to 
identify eligible patients [121]. Momentous decisions should still be evidence-based. 
An age of ≥ 65 is commonly defined as being elderly [122]. Chronic use of 5 or more 
systemic relevant drugs is a common definition of polymedication [123]. All selection 
criteria still are not evaluated to identify patients with a higher benefit of a Medication 
Management but are rather arbitrary. In addition, such criteria might include far too 
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many patients, taken the number of pharmacists into account who can offer a 
comprehensive Medication Management in Germany.  
 
1.3.1. THE EPHOR CRITERIA 
 
Approaches have been done by the PCNE in a workshop to evaluate risk parameters 
for DRPs. The "Ephor criteria" or "Ephor filter" suggests several parameters relating 
to a high risk of drug therapy. The Ephor filter is a tool rating each presence or 
absence with certain multipliers and forming a score to express the level of risk [124]. 
The basic criteria of Ephor are intake of 5 or more drugs and a patient age of 65 
years or older. The Ephor and PCNE affiliated researchers suggest further alert 
parameters, which might increase medication risk and work as a precondition to 
apply the Ephor score [124]: 
• reduced renal function of <50 ml/min 
• reduced cognition (dementia and pre-dementia) 
• increased risk for falling defined as: patient fell once or several times in the 
preceding 12 months 
• signals of reduced adherence to therapy 
• not living independently (nursing home) 
• unplanned hospital admissions 
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Criteria of being at high risk are shown and rated in table 2. These citeria are age, 
number of drugs taken, number of drugs with a small therapeutic index, certain 
indications and kidney function. 
Tab. 2: The Ephor-score  
Parameter Specification Score 
Age (y) <65 
66-75 
76-85 
>85 
0 
1 
2 
3 
Number of drugs <6 
6-9 
>9 
0 
2 
4 
Drugs with small 
therapeutic index 
(Warfarin, Digoxin, 
Lithium, MTX, etc.) 
number number=score value 
Indications treated by 
pharmacotherapy 
CV, diabetes, 
anticoagulation, 
neurologic/psychiatric, 
asthma/COPD, NSAIDs, 
opioids, corticosteroids 
number of 
indications=score value 
Kidney function, GFR 
(mL/min/1,73 m²) 
 
>50 
31-50 
<31 
0 
2 
4 
 
The Ephor score is rather a suggestion than an evaluated tool and can help in patient 
screening. There are several limitations. The score is based on experience and not 
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on data. The steps in grading kidney function differ from the staging of the guidelines. 
The broad field "pharmacotherapy for neurologic/psychiatric diseases" is not very 
specific. Little is known about how these multipliers were evaluated. Isaksen et al. 
have suggested and tested criteria for medication-risk screening. These criteria are 
five or more drugs, ≥ 12 doses per day, four or more recent changes to the 
medication regimen, three or more chronic diseases, history of noncompliance, and 
presence of a drug requiring therapeutic drug monitoring (TDM) [125]. 
 
1.3.2. CARDIOVASCULAR DISEASE AS A HIGH-RISK FACTOR 
 
Dyslipidemia and atherosclerosis are the leading causes of most cardiovascular 
diseases and are known to be prevalent independent from modern lifestyle 
throughout history [126, 127]. Suitable markers for patients at risk for cardiovascular 
events within the subsequent 12 months were discussed in a working group for the 
US-American National Heart, Lung, and Blood Institute [128]. Established scores and 
risk calculators, such as the Framingham score, the PROCAM score, the risk 
calculator of the American Society of Cardiology and American Heart Association or 
the European Society of Cardiology favored Systematic COronary Risk Evaluation 
(SCORE) are mentioned in this study but were found not to be specific enough, as 
these tools were designed to calculate and predict the 10-year risk for cardiovascular 
events rather than the short-term risk [129–131]. Tools like the TIMI risk score 
(named after the Thrombolysis In Myocardial Infarction, TIMI group) are designed to 
calculate a more acute risk but are limited to certain indications like the acute 
coronary syndrom [132]. Diagnostic tools are another option. Measurement of 
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coronary artery calcification or carotis intima-media thickness sonography are options 
but are not available for pharmacists [133], neither are soluble markers like 
endothelin-1, von Willebrand factor, tissue-type plasminogen activator and soluble 
thrombomodulin, which are discussed in the mentioned survey [128]. A reduction of 
risk factors might not even correlate to a change in patient outcomes. For example 
even though high homocysteine levels are a certain risk factor for cardiovascular 
diseases, lowering homocysteine levels failed to show any clinical benefit in reducing 
cardiovascular events [134].   
A familial susceptibility and a genetic predisposition are the most likely underlying 
causes of dyslipidemia. Dyslipidemia and atherosclerosis can be further triggered by 
lifestyle, certain drugs, alcohol consumption and diseases like diabetes mellitus, 
systemic lupus and kidney disease. Statistics for Germany estimated that about 11% 
of the population can be diagnosed with dyslipidemia [135]. The DETECT study 
surveyed patients in German primary care practices and found that every second 
patient presented with dyslipidemia [136]. About 50% of these patients were 
incorrectly diagnosed despite clear laboratory data and only 10% of the patients 
treated matched the NCEP-defined targets, indicating a low consciousness regarding 
blood lipids among physicians and patients alike [137]. LDL-cholesterol has proven to 
match best with atherosclerotic progression and clinical endpoints while other 
laboratory data such as homocysteine have shown to be risk markers but not a 
reasonable target of drug therapy [138]. Intensive LDL-cholesterol lowering with 
statins can reduce mortality and cardiovascular events [139–141]. This might be not 
only true for the highest risk patients (defined as >10% risk for a cardiovascular event 
over 10 years) but as well for patients with a lower risk [142]. Current guidelines 
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demand a LDL-cholesterol goal of <70 mg/dl [138, 143]. Results of the IMPROVE-IT 
study and studies with the proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitor evolocumab and alirocumab suggest, that an even lower LDL-cholesterol 
might correlate with better outcomes [144–147]. The reduction of the cardiovascular 
risk is independent of the patient’s age as shown in a large study in 2009 [148]. 
Community pharmacists succeeded to reduce LDL-cholesterol by implementing a 
lipid management program [149]. Another study came to similar results in 2005 [150]. 
A meta analysis found a 17.5 mg/dl stronger reduction in LDL-cholesterol in the 
intervention groups after pharmaceutical interventions compared to the control 
groups with standard care [49].  
 
1.3.3. RENAL FUNCTION AS A HIGH-RISK FACTOR 
 
The renal function declines with age in a natural way [151]. Cohen et al. found that a 
reduction of 1,18 ml/min per year can be expected in patients with multiple 
diseases [152]. Decreased renal function has shown to correlate with cardiovascular 
events in several surveys, including the large HOT and HOPE studies [153–158]. As 
many drugs need to be adjusted to renal function, kidney disease is a frequent 
source of DRPs [159]. Serum creatinine and patient characteristics like age and 
weight are accessible in most settings and hence the estimated glomerular filtration 
rate (eGFR) can be calculated. The Cockcroft-Gault equation is an evaluated tool, 
but many other equations were found to be clinically useful, like the MDRD and the 
new CKD-Epi equations [160–163]. In case of obesity, defined as having a BMI >30 
kg/m2, the Cockcroft-Gault equation tends to overestimate the eGFR, as it increases 
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with body size to a much lower extent [164]. As the lean body mass (LBM) has 
shown to correlate much better with the real eGFR [165, 166], it was suggested to 
utilize the LBM in the Cockcroft-Gault equation instead of the actual body weight in 
such cases. The estimated LBM (eLBM) can be calculated using the James 
equations [167]: 
Men: eLBM = 1.1 x weight(kg) – 128 x (weight(kg)/height(cm))2 
Women: eLBM = 1.07 x weight(kg) – 148 x (weight(kg)/height(cm))2 
The US-American National Kidney Foundation (NKF) program of Kidney Disease 
Outcomes Quality Initiative (KDOQI) defines 5 stages of kidney function [162]: 
• stage 1, normal GFR with a eGFR of ≥ 90 mL/min/1,73m2 
• stage 2, mildly decreased eGFR at 60-89 mL/min/1,73m2 
• stage 3, moderately decreased eGFR at 30-59 mL/min/1,73m2 
• stage 4, severely decreased eGFR at 15-29 mL/min/1,73m2) 
• stage 5, kidney failure at eGFR <15 mL/min/1,73m2 
The Kidney Disease Improving Global Outcomes (KDIGO) classification has similar 
grades G1-G5, grade 3 being subdivided into 45-59 mL/min/1,73m2 as G3a (mildly to 
moderately decreased) and 30-44 mL/min/1,73m2 as G3b (moderately to severely 
decreased) [168]. Both staging systems are used in international studies. 
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1.3.4. AGE AS A HIGH-RISK FACTOR 
 
Age is an independent risk factor in cardiovascular disease and is an Ephor criterion 
for high risk in polymedication as well. The elderly patient is defined here as a patient 
at an age of 65 years or older. The definition of being elderly differs widely and is 
related to biological aging more than to chronological aging. In many guidelines the 
term elderly is not even defined and differs [169]. Most industrial societies and the 
WHO simplify the definition by using the age of 65 or the retirement age [170]. 
Geriatric age in contrast is mainly defined as an age of >70 years in industrial 
societies, as e.g. per definition of the German Society of Geriatrics [171].  
 
1.3.6. MULTIMORBIDITY AND POLYMEDICATION 
 
Multimorbid patients with cardiovascular diseases are a major patient group in 
pharmaceutical practice. A study by van Bossche et al. found the diseases 
hypertension, lipid metabolism disorders, chronic low back pain, diabetes mellitus, 
osteoarthritis and chronic ischemic heart disease as typical patterns of diagnosis in 
multimorbid patients [172]. Cardiovascular diseases nowadays are major causes of 
death in Germany (table 3) [173, 174]. 
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Tab. 3: Mortality by disease, according to data of the German 
Center of Gerontology 2009 [174]. Cardiovascular diseases 
are displayed in blue script 
rank male female 
1 coronary artery disease coronary artery disease 
2 cerebrovascular diseases cerebrovascular diseases 
3 lung cancer chronic heart failure 
4 chronic heart failure hypertension 
5 respiratory tract diseases Alzheimer disease and dementia 
6 prostate cancer diabetes mellitus 
7 colorectal cancer breast cancer 
8 influenza and pneumonia arrhythmia 
9 hypertension influenza and pneumonia 
10 diabetes mellitus respiratory tract diseases 
 
Polymedication or polypharmacy, as another inclusion criteria, is commonly defined 
as the permanent use of 5 or more systemic available drugs [175]. Polymedication is 
increasing in industrial societies. In an epidemiologic study Hovstadius et al. showed 
an increase of 8.2 % in the prevalence of polymedication during a 4-year period from 
2005-2008, covering the entire population data for Sweden [176]. Polymedication is 
expected to be a major cause of DRPs [177]. With a higher number of drugs, the 
relevance of drug-drug interactions is increasing and prescription cascades, in which 
adverse drug reactions are treated with further drugs, are more likely [178]. 
Polymedication is associated with a higher risk of hospitalization [179]. On the other 
hand, polymedication might as well be indicated in case of multimorbidity. Payne et al. 
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showed for patients with a similar number of prescribed drugs, that the risk for 
hospitalization is relatively lower for those with a higher number of diagnoses, 
indicating that a high number of diagnoses makes polymedication more 
reasonable [180]. National regulations are believed to have a profound impact on 
polymedication. Facing the challenges of rising costs in the health care systems, 
different approaches were tried to reduce the economic burden. While the United 
States have implemented managed care to reduce the costs at an unchanged or 
even higher quality of care [181], Germany has established budgets for health 
services and medication, which led to a distinct drop in the number of drugs 
prescribed per patient [182]. Drug budgets may have certain disadvantages but make 
prescriptions of drugs without an indication more unlikely compared to other 
regulation systems. 
 
1.4. INTERPROFESSIONAL COLLABORATION AND MEDICATION 
RECONCILIATION 
 
Collaboration of physicians and pharmacists have become a major aspect in 
Pharmaceutical Care. Bringing pharmaceutical expertise into the medication process 
of the prescriber has shown to be beneficious for medication safety [183, 184]. 
Medication Reconciliation is a key activity to demonstrate the advantages of 
interprofessional cooperation. Numerous studies found discrepancies in up to 88% of 
participating patients [185–187]. The experience of many years of collaborative care 
clearly favors interprofessional approaches [30, 188–191]. The emphasis on 
interprofessional cooperation with the participation of physicians, pharmacists and 
other health-care specialists is expected to show a greater potential in improvement, 
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compared to medication safety and therapy management programs by a single 
profession alone. This assumption is supported by the German PRIMUM study [192], 
which was based on a Medication Management of general practitioners alone but 
failed to show a significant change in the MAI score, according to narrative 
information by the study's principal investigator Muth [192]. It is strongly believed that 
optimizing a patient’s therapy as well as reducing a patient’s medication risk can only 
be provided by a health care team consisting of different professions [193], albeit 
clear evidence for the benefits of interprofessional collaboration in a health care team 
is missing [30, 194]. 
 
1.4.1. ACCEPTANCE  
 
Under most jurisdictions pharmacists are not permitted to prescribe new drugs to 
patients. Great Britain and most provinces in Canada implemented changes to these 
restrictions during the last decade and granted prescription rights to pharmacists in 
certain settings [195, 196]. In most other countries pharmacists need a close 
collaboration with physicians to implement the findings from a Medication 
Management. German pharmacists can perform patient counselling to cope with 
DRPs regarding adherence and handling, but any changes on starting, stopping or 
adjusting the dosage of a prescription drug needs to be approved by a physician to 
be implemented. Interprofessional collaboration is the bottleneck in Medication 
Management. Recommendations on therapeutic changes can only reach the patient 
if the physician accepts the intervention. Thus, for a meaningful Medication 
Management, a good communication between the health care providers is essential. 
A few studies have assessed the physician’s acceptance of pharmaceutical 
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suggestions following a Medication Management. Chau et al. obtained an 
implementation rate of 46.2% of interprofessional recommendations in a recent study, 
undertaken in a community setting in the Netherlands [197]. In nursing home or 
hospital settings a higher implementation rate of 75.6% and 90.0%, respectively, 
could be reached [27, 198]. The interprofessional acceptance might be influenced by 
the health care system and the historical orientation of the professions. Potential 
professional barriers and obstacles can affect the collaboration between physicians 
and pharmacists in Germany as well as in any other country.  
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2. AIM AND OBJECTIVES 
 
As Medication Management is emerging as a future core activity of pharmacists, 
specific national data is required to demonstrate its potential benefits. Medication 
Management is based on enhanced clinical skills of the pharmacist. Currently, 
national data for Germany is scarce. A future implementation into standard care 
should be based on evidence. All research should serve the patient and meet the 
society`s requirements.  
The aim of this investigation was to evaluate an interprofessional collaborative 
Medication Management in Germany. The following objectives were defined:  
• to show the influence of Medication Management on the quality of drug 
therapy and the number of DRPs 
• to develop an approach for evidence-based patient selection for Medication 
Management  
• to assess the results of Medication Reconciliation regarding patient safety 
• to examine the acceptance of the pharmaceutical interventions by the general 
practitioners 
The results should allow an appraisal of the effects of a Medication Management in 
outpatient care, provide information on the extent of interprofessional collaboration 
and give a first impression on patient benefit. Criteria for an evidence-based patient 
selection might help to make Medication Management more effective. The outcomes 
of these analyses might permit to focus a Medication Management to meaningful 
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aspects and provide data to support an implementation into German health care and 
reimbursement systems. Data on Medication Reconciliation could provide an 
impression, whether the physician is missing relevant information and whether it can 
be provided through an interprofessional Medication Management. 
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3. METHODS 
 
All analyses in this work are based on data of the “WESTphalian study on a 
medication therapy management and home care-based intervention under Gender 
specific aspects in Elderly Multimorbid patients” (WestGEM study [199]. The study 
was registered at the ISRCTN registry ISRCTN41595373/ DOI 10.1186 and funded 
by the European Union and the state of North Rhine-Westphalia by the “European 
Regional Development Fund” program (project number: GW 2076). The funders had 
no influence in study design, data collection and analysis, decision to publish, or 
preparation of publications. Written informed consent was obtained from all individual 
participants included in the study (Appendix 1). The written statement was obtained 
from the patient by the general practitioner. One copy was archived by the general 
practitioner, one copy was handed to the patient. Clinical research associates 
confirmed obtainment of the written informed consent during clinical on-site 
monitoring. Included patients carried a participation pass throughout the study 
(Appendix 2). The study protocol was approved by the responsible local Ethics 
Committee in the Westphalia-Lippe region (approval number AKZ-2013-292-f-s). The 
study was conducted according to the principles of the Declaration of Helsinki [200]. 
The development of the intervention was based on the Medical Research Council 
guideline for the development and evaluation of randomized controlled trials [201]. It 
was piloted with seven general practitioners, two pharmacists and two home-care 
specialists. 
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3.1. STUDY DESIGN 
 
3.1.1. STUDY SETTING 
 
The study was conducted in an outpatient primary care setting in two model regions 
in North Rhine-Westphalia, Germany. Both regions had a different network structure. 
Outpatient health care in region A was organized as a network including general 
practitioners (n ≈ 15) and specialists (n ≈ 18). Outpatient health care in region B did 
not present in any network structures (number of general practitioners ≈ 55). 7 GPs 
of region A and 5 general practitioners of region B participated as study physicians. 
Home-care specialists in region A were social workers engaged by the county of 
Steinfurt. Home-care specialists in region B were social workers of the “Verein Alter 
und Soziales e.V.”, which is in charge of home care counselling in the county of 
Warendorf. The team of study pharmacists comprised of a team leader and clinical 
experts, who were experienced in pharmacotherapy and Medication Management. 
The group collaborated and communicated via webinars, telephone and e-mail. Each 
SOAP form (professional, see Appendix 5) was controlled by a second reviewer and 
the team leader, before it was handed to the physician. The documentation of the 
WestGEM study was based barely on data of the general practitioner to be 
comparable to the control phase and to assess the implemented effects and not just 
the pharmacists’ impressions. The setting and the workflow are shown in fig.1. 
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Fig. 1: Setting and workflow 
 
A consensus between all health care providers was likely to support the therapy. 
Existing barriers between the professions needed to be identified and solutions to 
overcome these obstacles should be implemented [202–204]. The elaborations 
therefore had a strong focus on collaboration and interprofessional cooperation. The 
three health care professions physicians, pharmacists and home care specialists 
worked closely together. The interprofessional approach combined case 
management routines of home care specialists with information gained during the 
interprofessional Medication Management by the specialized study pharmacists. In 
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the WestGEM study the home care specialists provided their insights to the 
pharmacists. Pharmacists performed the Medication Reconciliation and Medication 
Management with a strong focus on medication safety and pharmacotherapy. The 
general practitioners could outweigh the suggestions and choose the best approach 
for the patient.  
 
3.1.2. INCLUSION AND EXCLUSION CRITERIA 
 
The study included elderly multimorbid outpatients with polymedication. Inclusion 
criteria of the WestGEM study were an age of 65 years or older, at least 3 chronic 
diseases in 2 organ systems with at least one being a cardiovascular disease and at 
least one being present for 9 months or longer, use of 5 or more systemic drugs, 
given formal consent on participation in the study and a history of at least one visit to 
the general practitioner during each the past 3 quarters. Exclusion criteria were an 
insufficient ability to speak or read German, participation in other studies and the 
existence of severe illnesses probably lethal within 12 months, according to the 
general practitioner’s estimation. 
 
3.1.3. INTERVENTION 
 
All patients received standard care at baseline and during the control phase. On the 
intervention group, pharmacists performed a PCNE type-3 comprehensive 
Medication Review [38]. Pharmacists received the patient data of the general 
practitioner in a case report form (CRF). The home care specialists, who visited the 
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patients at home, pseudonymized all patient data. At this encounter a brown bag 
review was performed as well as an intense patient interview, covering all the 
questions a pharmacist would ask the patient. The home care specialists followed a 
concise query developed in cooperation with the pharmacists (Appendix 4) and 
evaluated the demand of the patient for home care devices or products, social and 
financial support and identified tripping hazards and potential risks. The pharmacists 
transferred all provided data to a calculation sheet for statistical purposes and 
developed a message form to the general practitioner based on a SOAP note form 
(Appendix 5). In a first attempt, the data on drug therapy of the brown bag review 
was compared to the medication plan of the general practitioner (Medication 
Reconciliation). Deviations were registered and possible explanations were assumed 
and added. Based on the CRF-reported diagnoses, the laboratory data and the chief 
complaints, individual therapeutic goals were generated and the estimated 
glomerular filtration rate (eGFR) at baseline was calculated using the Cockroft Gault 
equation [160]: 
 
For patients with a BMI of ≥ 30 kg/m², body weight was corrected and the lean body 
mass was used as described in chapter 1.3.3. [167].  
The pharmacotherapy was assessed on: 
• concordance between the prescribed and the taken medicines 
• guideline concordance 
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• patient goals 
• drug-drug interactions 
• difficulties in handling the drugs 
• intake and drug-food interactions 
• duration of therapy 
• therapeutic monitoring 
• geriatric use 
• indications without a drug 
• drugs without an indication 
• therapeutic doublets 
• toxicity/dose 
• adverse drug events 
• potentially inappropriate medication according to the PRISCUS list [205]  
• costs 
Depending on the patient`s individual situation, further problems were assessed. The 
patient goals from the assessments were taken into account and were regarded with 
high priority in the Medication Review. Pharmacists discussed possible interventions 
in the assessment part of the SOAP note and generated a new medication plan. 
Suggestions for monitoring parameters and patient counseling were made. An 
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estimation on the patient`s individual falling risk was provided to the home care 
specialists, who used this information for their own intervention (prevention, 
recommendation of daily living aids, etc.). 
 
3.1.4. MEDICATION RECONCILIATION 
 
Medication Reconciliation leads to disclosure of otherwise unknown medication of the 
patient to all health care providers [206]. In this elaboration, the patient was assessed 
twice and a brown bag review was performed at each encounter. Drugs that were 
found but were not documented by the general practitioner were investigated further. 
Each drug that was not on the medication plan of the general practitioner was listed 
in a table. To get a deeper impression on the relevance of the drugs that were not 
documented, they were categorized under risk and indication aspects. In a first step it 
was rated whether the drugs were believed to be relevant to the general practitioner 
or less important. Relevance was given if drugs needed clinical monitoring or caused 
considerable effects on organ systems. Drugs were categorized less relevant if they 
had a limited systemic effect or seemed to be used only in acute situations (i.e. eye 
drops, topical or cold-relief medication). Sedative drugs were identified using 
pharmaceutical expertise. Potential inadequate medication for the elderly was 
identified by the PRISCUS list. Furthermore, all drugs were classified as carrying a 
high risk for hospitalization if they were related to the following groups: 
anticoagulation, cardiac glycosides, cytostatics, diuretics, antidiabetics with risk of 
hypoglycemia, salicylates or disease-modifying antirheumatic drugs (DMARDs). 
These categories were chosen according to previous studies [207, 208]. High-cost 
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drugs were defined by German law as a price of >1200 € per package [209]. All 
drugs were further screened for a relation to cardiovascular, pain-related, 
psychoactive, gastrointestinal or pneumologic medication (indication clusters). Drugs 
that were not documented by the prescriber were documented, to get an impression 
on the importance of the collaborative aspects in Medication Management. Drugs 
were not evaluated on the patient level, all data for this assessment was obtained 
only from the documentation of the general practitioner. Research on Medication 
Reconciliation was qualitative and descriptive. Cases of not documented drugs were 
counted, percentages were calculated. 
 
3.1.5. PRIMARY ENDPOINT 
 
One of the main objectives of the WestGEM study was to determine whether the 
complex intervention could change the quality of the medication. Therefore, the 
Medication Appropriateness Index (MAI) was chosen as the primary endpoint. It was 
measured at baseline (t0/t1, CRF 1&2), 3 months (t2, CRF 3), 6 months (t3, CRF 4), 9 
months (t4, CRF 5), 12 months (t5, CRF 6) and 15 months (t6, CRF 7) was compared 
by rating the 10 items indication, effectiveness, dose, correct directions, practical 
directions, drug-drug interactions, drug-disease interactions, duplication, duration, 
and costs.  
The ratings resulted in a weighted score that served as a summary measure of 
prescribing appropriateness [48, 61, 62, 64, 210]. For each drug the 10 items were 
rated as appropriate, marginally appropriate or inappropriate. The item was rated 
with zero points for appropriate and marginally appropriate. Inappropriate items were 
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weighted with 1-3 points according to Samsa et al. (table 4) [64]. A maximum score 
of 18 could be achieved per drug. The score of each drug was summated as the 
patients individual MAI score. 
Tab. 4: Weighting of inappropriate ratings per MAI item 
according to Samsa et al. [64]  
item# item criterion weighted score 
1 Is there an indication for the drug? 3 
2 Is the medication effective for the condition? 3 
3 Is the dosage correct? 2 
4 Are the directions correct? 2 
5 Are there clinically significant drug-drug interactions? 2 
6 Are there clinically significant drug-disease interactions? 2 
7 Are the directions practical? 1 
8 Is this drug the least expensive alternative compared with 
others of equal utility? 
1 
9 Is there unnecessary duplication with other drugs? 1 
10 Is the duration of the therapy acceptable? 1 
 
For the study it was hypothesized that the pharmacists’ intervention would improve 
the quality of medication by lowering the MAI score, as well as reducing DRPs. The 
choice for the MAI as the primary endpoint was done in consideration of a Cochrane 
review by Patterson et al., describing which interventions are effective in improving 
the appropriate use of polymedication, reducing drug-related problems in older 
people and avoiding hospital admissions [65]. The review reports that the majority of 
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the included high-quality studies (seven out of eleven) used the MAI as the primary 
endpoint. 
3.1.6. SECONDARY ENDPOINTS 
 
Additional information regarding the quality of drug therapy is obtained from 
assessment instruments used by the study pharmacists within their Medication 
Management: 
• the number of DRPs, classified according to PCNE version 6.2  
• the prevalence of inadequate medication, detected by the PRISCUS-list [205]  
As discussed above the PCNE classification of DRPs was evaluated extensively and 
is frequently used in pharmaceutical care studies [77]. The PRISCUS list summarizes 
potentially inadequate medication (PIM) in the elderly and covers the drugs currently 
available in Germany [205]. It is well established in primary care medicine. 
 
3.1.7. TIMELINE AND WORKFLOW 
 
The WestGEM study was designed as a cluster-randomized controlled trial, 
incorporating qualitative analysis [199]. Qualitative analysis was performed during 
intervention development and piloting. Furthermore, qualitative methods were applied 
to perform a process evaluation of the randomized trial and to assess the acceptance 
of the interprofessional Medication Management approach. The study design was 
developed in line with the CONSORT statement extension to cluster RCT [211]. The 
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cluster design was chosen to avoid spillover effects among patients of a certain 
practice. The study protocol followed a stepped-wedge design (see 3.1.8.). All 
patients treated by one general practitioner switched from the control to the 
intervention group at the same time. Patients’ recruiting process, randomization 
routines and the applied documentation forms and data collection procedures were 
reappraised by a study nurse.  
All practices were initially assigned to the control group. After a 6-month observation 
period, general practitioners randomly entered one of the three clusters. Each cluster 
consisted of 4 practices. The interprofessional Medication Management approach 
was implemented sequentially in each cluster with a lag time of 3 months. During the 
Medication Management process, the general practitioners provided patient-specific 
data to the home-care specialists. The home-care specialists visited the patients and 
performed several patient interviews and assessments, including a brown bag review 
and a specifically developed standardized pharmaceutical questionnaire. They 
provided the pseudonymized results to the pharmacists. The pharmacists performed 
a comprehensive Medication Review (PCNE type-3) including Medication 
Reconciliation and supplied it to the home-care specialists, who allocated the 
Medication Review to the patient and handed it to the general practitioner. This 
procedure was repeated after 6 months. Each patient stayed in the intervention 
phase for 12 months. All primary and secondary endpoints were assessed at 
baseline and 6 months retrospectively as well as 3 months, 6 months, 9 months, 12 
months and 15 months post baseline (fig.2).  
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Fig. 2: Study timeline 
 
Patients recruited by the general practitioners received standard treatment during the 
control phase. Patient information was documented in a Case Report Form (CRF) 
(Appendix 3) by the general practitioner. The general practitioner’s documentation 
was chosen as the only source for all data to ensure a proper comparison with the 
control phase. This approach was done even if there were obvious discrepancies 
between the general practitioner`s and the home-care specialist`s documentation. 
The feasibility and acceptance of the workflow was tested in a pilot phase. 
 
 
 3. Methods / p.50 
 
 
3.1.8. STEPPED WEDGE DESIGN AND SAMPLE SIZE CALCULATION 
 
A stepped wedge design was chosen for this cluster-randomized control trial. The 
stepped wedge design can be described as a modified cross-over design and has 
certain advantages and disadvantages [212]. A clear advantage is that every patient 
and every general practitioner enters the intervention phase sooner or later. The total 
number of patients is reduced as every patient serves as member of the control and 
intervention group. A disadvantage is the limited flexibility of the intervention in time. 
Delays in provision of the patient assessment or the performance of the Medication 
Review might lead to biased results. The sample size calculation for the stepped 
wedge design was based on Woertman et al. [213]. As there were no comparable 
studies investigating the effect of collaborative Medication Management, an effect 
size of Cohen’s d=0.25 was considered as clinically and socially relevant. Based on 
this assumption and using a two-tailed t-test with a statistical power of 80% and a 
significance level (α) of 0.05 a total unadjusted sample size of 502 was calculated. 
An assumption of 20 patients per practice and little correlation between the clusters 
(ICC = 0.05) led to a design factor of 0.383 in the present stepped wedge model. 
Adjusting the sample size with the design factor and considering a maximum drop-
out rate of 20% the final sample size was calculated to be 240.  
 
3.1.9. RANDOMIZATION AND PATIENT RECRUITEMENT 
 
Participating practices were randomly allocated to one of the three study arms. A 
biometrician, not involved in the field work, randomly selected the practices. To avoid 
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changes in physician’s prescription behavior, random lists remained concealed until 
each allocation date. The participating general practitioners carried out the 
recruitment of the patients. To avoid selection bias, patient’s inclusion comprised of 
two steps. At first general practitioners systematically identified patients who were 
generally eligible for study inclusion by screening all patients for the defined in- and 
exclusion criteria. Potential study patients were listed in alphabetic order and were 
numbered consecutively (basic population). General practitioners then entered 
gender, age, and conditions in that list. In a second step, physicians forwarded a 
pseudonymous version of the recruitment list to the biometricians of the Institute of 
Medical Statistics, Informatics and Epidemiology (IMSIE, University of Cologne), who 
determined a random sample of 40 patients. The potential participants were informed 
about the study subsequently at routine-care appointments and asked to join the 
study, until a total of 20 patients per practice were listed. After giving informed 
consent, baseline documentations forms and questionnaires were completed. For 
every patient of the sample list who declined participation, a new patient was drawn 
from the basic population.  
 
3.1.10. DATA COLLECTION  
 
The WestGEM study was conducted from July 2012 till June 2015. The intervention 
phase started at January 1st, 2014. Patients were evaluated at baseline (t0/t1, 
CRF1/2), 3 months post-baseline (t2, CRF3), 6 months post baseline (t3, CRF4), 9 
months post-baseline (t4, CRF5), 12 months post-baseline (t5, CRF6) and 15 months 
post-baseline (t6, CRF7). Baseline documentation included a retrospective 
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assessment period over six months. Provided patient data was based on the general 
practitioner’s patient record and on the generated information of the home-care 
specialists. The general practitioner’s record included the anamnesis, laboratory data, 
medication and specific assessments done for the study, like the mini–mental state 
examination (MMSE) on cognitive state [214] and the Tinetti-test on mobilty [215]. 
Diagnoses were classified according to the International Statistical Classification of 
Diseases and Related Health Problems, version 10, German modification (ICD-10-
GM) of the WHO [216].  
The home-care specialists performed a brown bag review at the patients’ home 
including name and registration number (Pharmazentralnummer) of the taken 
medicine, the origin of the prescription (general practitioner, specialist or in case of 
non-prescription drugs the pharmacist), the taken dose according to the patient, the 
dosage form, chronic or as needed use, whether the drug was taken with food or 
fasting and the indication stated by the patient. Home-care specialists conducted a 
patient interview, with 34 defined pharmaceutically relevant domains, like the 
Morisky-questions on adherence [217] or a visual analog scale (VAS) pain 
assessment [218] and did their own home-care assessment as well (Appendix 4). 
During the study the pharmacists gathered the data 7 times regarding the general 
practitioners’ assessments and 2 times regarding the home-care specialists’ 
information and transferred all data into a calculation sheet. Checklists of DRPs, 
drug-drug interactions, MAI and MRCI were added to the pharmaceutical workup. In 
these elaborations, an interaction was rated as clinical relevant if further action, like a 
proposed intervention, seemed to be necessary. Only severe and relevant 
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interactions were reported to the general practitioner and suggestions on a potential 
solution were provided along with each interaction. 
 
3.1.11. QUALITY ASSURANCE 
 
To ensure data quality and to reduce missing data or processes which are not 
adherent with the study protocol, clinical research associates visited the general 
practitioners for clinical monitoring. Furthermore, several routines were established to 
prevent or detect incorrect as well as inconsistent data entry and incomplete data. In 
case of missing documentation, the general practitioners were asked to complete the 
information subsequently. The data of the home-care specialists was consecutively 
compared with the pharmacists’ data and thoroughly provided. 
 
3.1.12. ETHICAL ASPECTS 
 
The study protocol and all study forms were approved by the ethics committee of the 
Medical Association of Westphalia-Lippe (Aerztekammer Westfalen-Lippe), approval 
number AKZ-2013-292-f-s and conducted to the principles of the World Medical 
Association (WMA) Declaration of Helsinki. Written informed consent was obtained 
from all individual participants included in the study by the general practitioner. One 
copy was archived by the general practitioner; one copy was handed to the patient. 
Clinical research associates proved obtainment of the written informed consent 
statement during clinical on-site monitoring. The ethics committee of the Medical 
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Association of Westphalia-Lippe has approved this procedure. The study was 
registered at the ISRCTN registry. 
 
3.2. STATISTICAL METHODS 
 
For descriptive statistics, patient characteristics were described using mean ± 
standard deviation (SD) or count (percentages). Corresponding p-values are from 
Fisher’s exact test (qualitative data) or Kruskal-Wallis test (quantitative data), 
respectively. The confirmatory calculations of the primary and secondary endpoints 
were based on the intention-to-treat (ITT) population (initial treatment assignment). A 
Mixed Model with a significance level of 5% was created with the summated MAI 
score per patient as the dependent variable.  
The analysis on patients with a major benefit from the Medication Management was 
based on logistic regression. In a first step the association between possible 
predictor variables and a greater benefit status was analyzed using univariate logistic 
regression models. Variables with similar content were selected by taking the 
variable with lowest p-value in univariate logistic regression for further analysis into 
account. The univariate regression was done to assort the variables. In a second 
step a multiple logistic regression model with stepwise backward selection (likelihood 
ratio test, p-value for inclusion 0.05, p-value for exclusion 0.1) was performed. 
Additionally, possible cut-off values for quantitative variables were computed with 
Receiver Operating Characteristics (ROC). For logistic regression models Odds 
Ratios (OR) with corresponding 95% confidence interval (CI) and p-values were 
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computed. For ROC-curves area under the curve (AUC) and corresponding 95% CIs 
are presented. All reported p-values are two-sided and considered statistically 
significant if lower or equal than 0.05. Calculations were performed using SPSS 
Statistics 22 (IBM Corp., Amnok, NY, USA) and STATA 14 (StataCorp., College 
Station, Texas, USA). 
 
3.2.1. EFFECT OF THE INTERVENTION ON MAI SCORE AND DRP 
 
Confirmatory analysis on changes in the MAI score and the number of DRPs were 
based on the intention-to-treat (ITT) population. A Mixed Model with a significance 
level of 5% was created, containing the summated MAI score per patient at 
documentation date two to seven (T1-T6) as the depending variable. The MAI 
baseline score, the documentation dates and the treatment status (intervention or 
control group) were regarded as fixed factors and the cluster as random factor. To 
detect the mere effect of the intervention, measured as the patient switch from the 
control phase to the intervention phase and from the intervention phase with the first 
assessment to the intervention phase with the second assessment, only the point in 
time in the Mixed Model was regarded, to which a score was retrieved in the 
comparable phase. The Mixed Model hence was expanded by so called contrasts 
[219], adding a time effect. The MAI score was compared at: 
• contrast 1 for the comparison of the control phase to intervention phase 1, 
resembling the principal switch into the intervention phase by the first 
assessment at documentation 4 and 5, 
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• contrast 2 for the comparison of intervention phase1 with intervention phase 2, 
resembling the transition to the second assessment.  
The DRP analysis was performed in a similar way. 
 
3.2.2. EFFECTS OF THE INTERVENTION ON LDL-CHOLESTEROL 
CONCENTRATIONS 
 
In this study LDL-cholesterol levels were obtained by the physician according to 
standard practice. LDL-cholesterol was measured indirectly by the collaborating 
laboratories using the Friedewald equation [220]:  
LDL-cholesterol = Total-cholesterol (TC) – HDL-cholesterol  – Triglycerides (TG)/5 
(mg/dL) 
It is unknown whether the contract laboratories of the general practitioners used 
corrections of the Friedewald equation, which might not be accurate with increasing 
Triglyceride levels >150 mg/dl [221]. 
For the evaluation of changes in LDL-cholesterol under controlled conditions in the 
stepped wedge design, laboratory data at several points in time were necessary. The 
laboratory data of the WestGEM study on LDL-cholesterol did not support a 
controlled approach as the general practitioners had drawn laboratory data under 
routine care only at inconsistent times of the study. Some general practitioners did 
not even test for LDL-cholesterol at all. During the study, general practitioners were 
free to order laboratory data and could handle the patients unchanged from daily 
practice. LDL-cholesterol levels hence were only provided according to the practice 
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of the general practitioner. LDL-cholesterol reduction was initially tested in a 
comparison of the levels at study entry (T0) and of the levels after the intervention 
(T3-T7). In case more than one level was available, the latest one was used. The 
patient’s LDL-cholesterol levels were summated and were tested for significance with 
a t-Test. In a second step, all patient data of each assessment (T0-T7) was analyzed 
in a Mixed Model. In case of missing data, the last obtainable level was carried 
forward, the so called Last Observation Carried Forward (LOCF) approach, missing 
LDL-cholesterol levels were filled with the previous level to have more consistent 
data [222]. In contrast to the before-after method, the Mixed Model considered the 
control and the intervention phase. In addition, the number of patients at target (<70 
mg/dl) was counted before and after the intervention.  
 
3.2.3. PATIENT SELECTION 
 
To analyze whether certain patient groups had a major benefit from the medication 
review and hence might be prioritized in a future setting, several patient parameters 
were tested and suitable indicators were searched for. For statistical purpose a MAI 
cut-off, defining a major benefit from a Medication Review needed to be defined. The 
cut-off must not derive from the study data. Unfortunately, the achievable reduction of 
the MAI score is very much depending on the setting. To avoid a mere arbitrary MAI 
score cut-off number to define a major benefit, a Cochrane Review by Patterson et al. 
was regarded as a benchmark [65]. Patterson et al. identified 5 studies on Medication 
Management as being of better quality. The mean reduction in the MAI score in these 
studies was 3.88 points. As the included studies carry a high relevance and came to 
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significant results, patients of the study with a reduction of ≥3.88 points in the MAI 
score were defined as having a major benefit from the intervention. 
In a first approach, explicit baseline characteristics that could be obtained early in the 
medication review process at the time of data collection and the initial patient 
interview were analyzed. These parameters were gender, age, eGFR, number of 
drugs in use at baseline, number of differences between the prescribed and used 
drugs, Cumulative Illness Rating Scale (CIRS-G) severity index [223, 224],, number 
of diagnoses, number of responsible health care providers (specialists and hospitals) 
and the number of visits to the general practitioner. Results here could lead to a fast 
selection of eligible patients by the pharmacist or health care professional.  
In a second approach, the implicit parameters baseline MAI score and the length of 
the Medication Management (length of the intervention) was tested along with gender, 
age, eGFR and the number of drugs at baseline as prediction factors. Data on the 
MAI score and the longitudinal service was generated later in the pharmaceutical 
work up during a medication review. The influence of these parameters on receiving 
a greater benefit status was analyzed in a multiple logistic regression model with 
backward selection (LR method) and the Odds Ratio was calculated. Possible cut-off 
values for quantitative parameters were computed with Receiver Operating 
Characteristics (ROC). The influence of these factors on developing a higher benefit 
status was analyzed in a multiple logistic regression model.  
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3.2.4. ACCEPTANCE ANALYSIS 
 
The acceptance of the pharmaceutical recommendations in the Medication 
Management was analyzed based on the general practitioners appraisal on the 
feedback form, which included a table enabling the general practitioner to respond to 
every single recommendation made by the pharmacists. General practitioners could 
rate their acceptance in 3 categories of approval: partial/complete, no action/refusal 
or further information requested. In this analysis, forms without any feedback and 
requests for further information were excluded. The feedback was subsequently 
allocated to one of the three domains of stopping an existing drug, starting a new 
drug or changing an existing drug’s dose. To identify covariates of the prescriber’s 
acceptance of the recommendations, an ordinary least squares (OLS) regression 
with the approval rate as the dependent variable was conducted. In a first approach, 
univariate analyses were performed and then all influential factors were considered 
within one model. The standard error was clustered at the practice level to adjust for 
correlations within physicians. The analyzed influential factors were: demography, 
nutrition, morbidity, drug therapy, intensity of physician-patient relationship, patient-
reported health, family support, cognitive impairment, mobility, patient’s daily 
functioning, adherence and duration of the interprofessional collaboration. 
To find out whether certain influential factors might lead to a higher or lower 
frequency in the physician’s acceptance of a suggested intervention, 3 categories of 
starting a drug, stopping a drug or changing a drug`s dose were tested versus the 
patient’s age, gender, education level, Body Mass Index (BMI), morbidity (CIRS-G), 
number of prescribed drugs, number of drug-related events, number of patient-
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reported adverse events, number of potentially inadequate medications (PIM), 
number of patient visits to the general practitioner per quarter (3 months), patient- 
reported health (Visual Analog Scale, VAS), social support (Questionnaire Social 
Support, short form 14 Items / Fragebogen soziale Unterstützung, Kurzform 14 Items, 
FSozu14), cognitive impairment (MMSE), mobility (Tinetti test), daily functioning 
(activities of daily living, ADL and instrumental activities of daily living iADL), and 
adherence (Morisky score) in a multivariate ordinary least squares (OLS) regression. 
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4. RESULTS 
 
4.1. STUDY POPULATION AND PATIENT BASELINES 
 
In the area of the city of Steinfurt 92 patients out of 7 general practitioner practices 
were included, in the area of the city of Ahlen 73 patients from 5 practices. 33 
patients could not finish the study and dropped out. Of these 33 patients, 7 patients 
died, 1 patient changed the general practitioner, 6 patients finished participation of 
the study due to moving to a nursing home, 17 for various reasons like worsening 
disease state, dementia or simply because of excessive involvement into the study 
(“annoying interviews”), in two cases the general practitioner stopped the 
participation of the patient in the study as the patients felt uncomfortable with the 
interviews. Data was sufficient for 142 patients, who comprised the ITT population for 
the MAI analysis. The most frequent diagnoses were related to the metabolic 
syndrome with hypertension, dyslipidemia, type 2 diabetes mellitus being among the 
most documented diseases (table 5). 
Tab. 5: Pattern of diagnoses in the ITT population (N=142) 
 
Disease (ICD-10 Code) Pat. (%) 
1 Hypertension (I10) 109 (76.8) 
2 Dyslipidemia (E78) 77 (54.2) 
3 CHD (coronary heart disease) (I25) 57 (40.1) 
4 Diabetes mellitus Type 2 (E11)  50 (35.2) 
5 AFIB (atrial fibrillation) (I48) 29 (20.4) 
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Further patient characteristics are shown in table 6 separately for the ITT-population, 
the patients included in the LDL-cholesterol analysis and the patients included in the 
acceptance analysis. The baseline values of the 3 clusters are very similar. 
Tab. 6: Further patient characteristics of the ITT-population 
and of the eligible patients for the LDL-cholesterol and 
acceptance analysis  
Parameter 
ITT population 
 
n = 142 
LDL-C analysis 
 
n = 92 
Acceptance 
analysis 
n = 103 
 Mean; N SD; % Mean; N SD; % Mean; N SD; % 
Age 76.7 6.3 76.2 6.0 77.0 620 
Gender (% female) 76 53.5 % 45 49% 68 54.5% 
Body Mass Index 28.4 4.3 28.6 3.8 28.4 4.3 
Morbidity (CIRS-G) 1.6 0.4 1.6 0.4 1.6 0.4 
No. of diagnoses 12.7 5.7 12.5 5.9 12.3 5.1 
No. of prescribed drugs 9.4 3.1 9.9 3.3 9.5 3.3 
No. of DRPs 7.3 3.4 7.3 3.2 7.3 3.5 
 
The available data allowed an inclusion of 142 patients for the analysis of changes in 
the MAI, 92 patients for the LDL-cholesterol analysis and 103 patients for the 
acceptance analysis. 
4.2. MEDICATION APPROPRIATENESS INDEX 
 
The MAI score was defined as primary endpoint. Results for each of the 10 items of 
the MAI score are shown in table 7.  
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Tab. 7: Effect of the Medication Management on the MAI 
score per cluster and item 
MAI 
item 
Total Cluster 1 Cluster 2 Cluster 3 
 
T0 
N=1261 
T6 
N=1283 
T0   
N=582 
T6   
N=585 
T0  
N=312 
T6  
N=311 
T0  
N=367 
T6   
N=387 
N % N % N % N % N % N % N % N % 
1 197 16 96 8 87 15 30 5 61 20 34 11 49 13 32 8 
2 261 21 131 10 102 18 39 7 88 28 45 15 71 19 47 12 
3 353 28 203 16 133 23 63 11 124 40 70 23 96 26 70 18 
4  358 28 201 16 138 24 61 10 117 38 71 23 103 28 69 18 
5 322 26 154 12 132 23 42 7 99 32 57 18 91 25 55 14 
6 251 20 170 13 118 20 74 13 71 23 45 15 62 17 51 13 
7 87 7 52 4 32 6 18 3 33 11 17 6 22 6 17 4 
8 82 7 43 3 40 7 20 3 29 9 13 4 13 4 10 3 
9 218 17 114 9 84 14 28 5 77 25 43 14 57 16 43 11 
10 118 9 86 7 46 8 32 6 39 13 27 9 33 9 27 7 
N=Total summated MAI score and MAI score per item for all included patients, 
%=Percentage of ratings per patient as not appropriate 
 
As the intervention was done longitudinal over time and interprofessional action was 
required, the German definition of Medication Management was fulfilled. The 
Medication Review was repeated after 6 months, home-care specialists visited the 
patients two times at home and the patients had at least 7 documented visits to their 
general practitioners. Patients entered the study in 3 clusters with a lag time of 3 
months between each. The MAI score was reduced (fig.3):  
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• for group 1 from a mean of 30.15 ± 24.14 at T0 to 14.09 ± 14,80 points at T6 
• for group 2 from 43,28 ± 30,95 to 24,47 ± 16,17 points 
• for group 3 from 26,07 ± 17,33 to 18,44 ± 14,67 points 
Patients who had experienced the intervention at an earlier time and thus benefited 
from the Medication Management for a longer time had a more pronounced effect 
compared to those who entered the study later (fig.3). Overall, the difference in the 
MAI score between control phase and intervention phase was 4.27 points (95-%-CI: 
2.36 – 6.18; p < 0,001) in the original study consideration. Hence a significant effect 
of the Medication Management in terms of a reduction of the MAI score was shown 
for the intervention-phase compared to the control-phase [225]. 
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Fig. 3: Graphical presentation of the effect of Medication 
Management per cluster over time 
 
4.3. DRUG-RELATED PROBLEMS AND POTENTIALLY INADEQUATE 
MEDICATION 
 
A secondary endpoint of the WestGEM study was the reduction of DRPs. DRPs were 
classified according to PCNE version 6.2 and were another indicator of the quality of 
therapy and medication safety (as described in chapter 1.2.4.). A total of 1588 DRPs 
were detected in 142 patients (cluster 1: 688 DRPs, cluster 2: 425 DRPs; cluster 3: 
475 DRPs). In the Mixed Model, a reduction of -0,45 DRPs could be shown in the 
intervention phase versus the control phase (p = 0,014). Comparable to the reduction 
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in the MAI score, the number of DRPs declined with a stronger effect over time. 
Reduction of DRPs again was more profound in cluster 1 with -2,63 DRPs compared 
to cluster 2 with -1,19 and cluster 3 with -1,02 (table 8). 
 
Tab. 8: Effect of the Medication Management on the number 
of DRPs 
Cluster No. of GPs No. of patients Δ of DRPs* p value 
1 4 59 -2.63 <0.001 
2 4 40 -1.19 0.009 
3 4 43 -1.02 0.006 
*Difference in no. of DRPs per patient at T0-T6 
 
DRPs were counted based on the documentation of the general practitioner, to be 
comparable to the control group. Hence, an initial increase of DRPs was expected 
with the general practitioner having more drugs on the list. In fig. 4 the increase of 
DRPs can be seen in cluster 2 and a slight increase in cluster 3.  
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Fig. 4: Graphical presentation of the effect of Medication 
Management on the number of DRPs 
 
In the same 142 patients the prevalence of inadequate medication, using the 
PRISCUS list was reduced from a total of 50 PIM drugs before (T0) to 40 PIM drugs 
at the end of the study (T6). The t-Test shows a p value of 0,347. The study revealed 
only a trend towards the reduction of PIM drugs but no significance. 
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4.4. LDL-CHOLESTEROL CONCENTRATIONS 
 
The obtained data on LDL-cholesterol was fragmentary, as the general practitioners 
performed routine care during the study and drew LDL-cholesterol samples 
according to their own budgets and responsibilities. For a total of 92 patients LDL-
cholesterol levels were available at baseline (before the study started) and at least 
once after the intervention. Individual patient data is shown in Appendix 9. Table 12 
shows the characteristics of eligible patients for the analysis of LDL-cholesterol 
values. Even though only 92 of 142 patients were eligible for the test, the 
characteristics do not differ profoundly from the whole study cohort. 
Tab. 12: Patient characteristics of eligible patients for the 
LDL-cholesterol analysis compared to the ITT population 
Parameter ITT population (SD,%) 
n = 142 
LDL-C population (SD,%) 
n = 92 Age (years) 76.7 (6.3) 
(6.3) 
76.2 (6.0) 
(6.0) Gender (female) [N (%)] 76 (53.5) 
(53.5) 
45 (49.0) 
(49.0) BMI (kg/m²) 28.4 (4.3) 
(4.3) 
28.6 (3.8) 
(3.8) Morbidity (CIRS-G) 1.6 (0.4) 
(0.4) 
1.6 (0.4) 
(0.4) No. of diagnoses 12.7 (5.7) 
(5.7) 
12.5 (5.9) 
(5.9) No. of prescribed drugs 9.4 (3.1) 
(3.1) 
9.9 (3.3) 
(3.3) No. of DRPs  7.3 (3.4) 
(3.4) 
7.3 (3.2) 
(3.2) 
 
 4. Results / p.69 
 
 
A stronger deviation can be found among the clusters, as shown in table 13. 
Tab. 13: Patient characteristics of eligible patients for the 
LDL-cholesterol analysis per cluster 
*according to the GP’s documentation. cluster 1: intervention after Jan.1st, 2014, 
cluster 2: intervention after April 1st, 2014, cluster 3: intervention after July 1st, 2014 
 
Fig. 6 presents clusterwise changes in mean LDL-cholesterol over time. The figure 
reveals that the LDL-cholesterol reduction happened between T3 and T4 in all 3 
clusters, which is unexpected, as the intervention started with a lag-time of 3 months 
between the 3 clusters. LDL-cholesterol levels seemed to be rather depending on 
seasonal fluctuation than on the Medication Management. Each cluster shows lower 
mean LDL-cholesterol levels at the end of the study as compared with study entry. 
Variable (mean) 
Cluster 1 
N=51 (SD) 
Cluster 2 
N=10 (SD) 
Cluster 3 
N=31 (SD) 
Total 
N=92 (SD) 
Age (years) 75.7 (6.699) 79.4 (4.904) 76 (4.934) 76.2 (6.022) 
BMI (kg/m2) 28.9 (4.174) 29.6 (2.749) 27.8 (3.502) 28.6 (3.843) 
Morbidity (CIRS-G) 1.8 (0.421) 1.6 (0.401) 1.4 (0.241) 1.6 (0.398) 
No. of diagnoses* 12.2 (6.232) 11 (4.570) 13.4 (5.795) 12.5 (5.920) 
No. of drugs* 10.3 (3.559) 10.4 (3.596) 8.9 (2.435) 9.9 (3.262) 
No. of DRPs 7.3 (3.142) 8.2 (3.765) 7 (3.027) 7.3 (3.156) 
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Fig. 6: Mean LDL-cholesterol concentrations (with LOCF) for 
the 3 clusters over time  
 
Descriptive results demonstrate a decrease of LDL-cholesterol values. The paired t-
test showed an overall significant LDL-cholesterol level reduction of -7.55 mg/dl (SD: 
28.39) from 114.1 mg/dl (SD: 36.35) at T1 (Baseline) to 106.5 mg/dl (SD: 35.8) at T6 
(after 15 months, with LOCF) (p = 0.012). The reduction in cluster 1 was 5.5 mg/dl 
(SD: 25.77), 5.8 mg/dl (SD: 25.28) in cluster 2 and 11.5 mg/dl (SD: 33.51) in cluster 3. 
Table 14 shows the mean LDL-cholesterol levels and the sample size during the 
study phase. 
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Tab. 14: Mean LDL-cholesterol reduction and sample size 
during the study phases (without LOCF) 
Patient group T1 T2 T3 T4 T5 T6 T7 
LDL-C (mg/dl) 114.09 91.80 102.69 104.64 98.00 104.55 102.39 
Patient N= 92 5 48 56 55 53 51 
 
According to current guidelines, most study patients could be classified as 
cardiovascular high-risk patients and had a LDL-cholesterol goal of <70 mg/dl [226]. 
At T1 only 5 of the 92 patients fell into the category of LDL-cholesterol <70 mg/dl 
whereas at T6 a total of 10 patients showed LDL-cholesterol levels of <70 mg/dl 
(Appendix 9).  
The Mixed Model calculations resulted in a greater reduction of LDL-cholesterol 
values for the intervention phase (-8.27 mg/dl, 95%-CI: -16.03 – -0.52) compared to 
the control phase (-4.81 mg/dl, 95%-CI: -14.1 – -4.5)). The mean difference between 
both groups in the Mixed Model was only -3.47 mg/dl and failed to reach statistical 
significance.  
 
4.5. IDENTIFYING PATIENTS WITH A GREATER BENEFIT OF A MEDICATION 
MANAGEMENT 
 
129 patients of the ITT population of the study met all criteria with a MAI score at the 
beginning (T0) and at the end of the study (T6) and were included in the analysis on 
patient selection criteria (table 10). 73 patients out of this group had a reduction in 
the MAI score of 3.88 or more and were considered as patients with a higher benefit 
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of a Medication Review, according to the chosen cut-off (as described in chapter 
3.2.3.). The results of the final model are shown in table 10. 
Tab. 10. Baseline characteristics of the studied patient group. 
Data is presented as mean ± SD unless otherwise indicated 
 
Parameter  Total 
Minor 
benefit 
Major 
benefit p value 
Collective   129  56  73   
Female Gender (%)  69 (53.5%) 30 (53.6%) 39 (53.4%) 1.000 
Length of the 
intervention 
12 months1 
9 months2 
6 months3 
54 (41.9%) 
32 (24.8%) 
43 (33.3%) 
17 (30.4%) 
13 (23.2%) 
26 (46.4%) 
37 (50.7%) 
19 (26%) 
17 (23.3%) 
0.017 
Age  76.4 ± 6.3 76.1 ± 6.4 76.7 ± 6.2 0.694 
eGFR  55.6 ± 21.5 59.6 ± 21.3 52.6 ± 21.3 0.071 
MAI*  31.3 ± 24.8 19.9 ± 16.0 40.0 ± 26.8 <0.001 
Nr. of drugs  9.4 ± 3.2 8.1 ± 2.3 10.5 ± 3.4 <0.001 
Nr. of 
discrepancies**  
 4.5 ± 3.5 3.3 ± 2.8 5.4 ± 3.7 0.001 
CIRS-G severity 
index 
 1.6 ± 0.4 1.6 ± 0.4 1.7 ± 0.4 0.090 
Nr. of diagnoses  13.1 ± 5.8 12.6 ± 5.1 13.5 ± 6.3 0.526 
Nr. of health care  
providers*** 
 3.0 ± 2.1 2.6 ± 1.7 3.2 ± 2.3 0.167 
Nr. of GP visits****  12.3 ± 8.4 12.7 ± 7.7 12.0 ± 8.9 0.396 
1cluster 1, 2cluster 2, 3cluster3, * Mean summated baseline MAI score per patient, 
**between GP-prescribed and used drugs, ***specialists and hospitals, ****(during 
past 6 months) 
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Based on this analysis, 4 influence factors on the status of having a high benefit from 
the Medication Review could be identified. These are the number of drugs in use 
(p<0.001), the number of differences between the prescribed and the used medicines 
(p=0.014), the baseline MAI score (p<0.001) and the time of change from the control 
to the intervention group (p=0.001). For each additional drug in use the chance of 
having a major benefit from a medication review increases 1.28 times and for each 
discrepancy between a prescribed drug and what is actually taken at home 1.18 
times.   
Multivariate regression on the parameters that are detectable at initiation of a 
Medication Review (approach 1) was significant for the number of drugs per patient 
(p=0.001) and the number of differences in drugs documented by the general 
practitioner and taken by the patient at home (p=0.014). 
Multivariate regression on the parameters that are typically generated later in a 
Medication Review (approach 2) was significant for the baseline MAI score (p<0.001), 
the time of change from the control to the intervention group (overall p=0.006) and 
again the discrepancy between prescribed and used drugs (p=0.009) (table 11). The 
chance of benefiting from a medication review rises by 1.06 per 1-point increase in 
the baseline MAI score. Patients who entered the medication review service 3 
months later than the first group and hence experienced a 3-month shorter 
intervention, had a fourfold reduced chance of having a major benefit from the 
medication review. Patients who entered the medication review 6 months later and 
experienced a 6-month shorter intervention had a 4.7 times lower chance of having a 
major benefit. Per each discrepancy between prescribed and used drugs the chance 
to have a major benefit from the medication review increases 1.21 times. 
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Tab. 11: Multiple logistic regression analyses after automatic 
selection, early detectable parameters (approach 1) and later 
detectable parameters (approach 2)  
Variable Comparison OR 95%-CI p-value 
Approach 1, early detectable parameters 
Number of drugs per patient 1 diff. 1.282 (1.109 to 
1.1482) 
0.001 
Number of differences in drugs 
between GP and patient 
1 diff. 1.181 (1.034 to 
1.350) 
0.014 
Approach 2, later detectable parameters 
Mean summated baseline MAI- 
score per patient 
1-point 
higher 
score 
1.061 (1.031 to 
1.093) 
< 0.001 
Length of the intervention   
 
 
 
 
 
0.006 
(overall) 
9  vs. 12 
months 
0.248 (0.078 to 
0.791) 
0.018 
6  vs. 12 
months 
0.211 (0.077 to 
0.578) 
0.002 
Number of differences in drugs 
between GP and patient 
1 diff. 1.206 (1.048 to 
1.387) 
0.009 
 
A receiver operating characteristic curve (ROC curve) was plotted to search for a 
MAI score, which could be a useful threshold in patient selection (fig. 5). The true 
positive (sensitivity) is plotted against the false positive rate (1-specifity), the value 
with the highest specificity and highest sensitivity (closest point in the graph to the 
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top left) corresponds to a potential cut-off number. The ROC analysis suggests that a 
potential cut-off for patients experiencing a major effect from a Medication 
Management could be a MAI score of ≥ 24 (AUC = 0.823, s.e. = 0.037). However, 
this cut-off level is only valid for the analyzed patient cohort of elderly multimorbid 
patients with polymedication and a similar patient baseline.  
 
 
Fig. 5: ROC curve on the MAI-score 
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4.6. MEDICATION RECONCILIATION 
 
Medication Reconciliation was the first step at performing the Medication Reviews in 
this study. It was soon realized that a high number of drugs was not documented by 
to the general practitioners. In total 1749 discrepancies in 142 patients were reported 
the general practitioners after the two patient assessments, with a total of 179 
different drugs. 125 (69,8%) of these drugs were rated as highly relevant to the 
general practitioner, 54 drugs were less relevant. Examples of relevant drugs were 
apixaban, candesartan, oxycodon, ticagrelor, or metformin. Drugs rated less relevant 
were for example algedrat, ambroxol, cetirizine, external nonsteroidal anti-
inflammatory drugs or nepafenac eyedrops. The rating was based solely on 
pharmaceutical expertise. 15 drugs had sedating effects and might increase fall risk, 
12 were listed in the PRISCUS list of potential inappropriate medication for elderly 
patients and 33 of the 179 drugs were associated to a high risk for hospitalization. 99 
drugs were classified as having a high potential for drug-drug interactions. Among 
these drugs for example were omeprazol but not pantoprazol and NSAIDs but not 
metamizol. With adalimumab, etanercept and imatinib three medications belonged to 
the high-cost group (>1200 €).  
To get a more defined impression, the 179 drugs were related to 5 clusters of 
indication. As a result, 58 cardiovascular drugs, 45 pain relievers, 48 psychoactive 
drugs, 57 gastrointestinal drugs and 42 respiratory drugs were found. Table 9 shows 
the 30 most frequently registered drugs that were taken by the patients but were not 
documented by the general practitioner, assorted by total frequency and with the 
correlating cluster of indication. There were no sedative and no PRISCUS drugs 
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among the 30 most frequently found discrepancies. Only 1 out of 142 patients 
showed no discrepancy between the prescribed and the actually taken medication. 
Tab. 9. The 30 most frequently drugs used by the patients but 
not documented by the prescriber 
Drug Registered cases Cluster of indication 
Diclofenac* 123 pain medication 
Magnesium 90 
 Ibuprofen  78 pain medication 
Acetylsalicylic acid   75 cardiovascular 
Calcium 55 
 Metamizole 55 pain medication 
Colecalciferol 51 
 Glycerol trinitrate 39 cardiovascular 
Macrogol 39 gastrointestinal 
Acetaminophen 35 pain medication 
Pantoprazol 34 gastrointestinal 
Tilidine 28 pain medication 
Metoprolol 25 cardiovascular 
Tamsulosin 25 
 Spironolacton 22 cardiovascular 
Hydrochlorothiazid 21 cardiovascular 
Furosemide 20 cardiovascular 
Sennosides 20 gastrointestinal 
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Drug Registered cases Cluster of indication 
Potassium 18 cardiovascular 
Loratadine 18 
 Gentamicin (eye drops) 17 
 Ginkgo biloba leaf extract 17 
 Timolol (eye drops) 17 
 Hyaluronic acid (eye drops) 16 
 Rivaroxaban 16 cardiovascular 
Candesartan 15 cardiovascular 
Simvastatin 15 cardiovascular 
Amlodipin 14 cardiovascular 
Torasemide 14 cardiovascular 
Loperamide 13 gastrointestinal 
*systemic and topic 
 
4.7. ACCEPTANCE ANALYSIS 
 
As a result of the Medication Reviews, 1705 recommendations for interventions were 
proposed by the pharmacists to the physicians on 142 patients during the WestGEM 
study., i.e. 12 recommendations per patient [227]. 1082 of these recommendations 
(63.5%) on 104 patients were rated by the physicians (Appendix 6) using the 
response form (Appendix 7). 667 of these feedbacks on 103 patients could be 
allocated to the 3 domains on stopping an existing drug treatment, starting a new 
drug treatment or changing the dose of an existing drug, whereas the other 
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interventions were not drug-related but for example on laboratory data, monitoring or 
patient education. Characteristics of patients eligible for acceptance analysis are 
shown in comparison to the ITT population in table 15. 
Tab. 15: Patient characteristics of eligible patients for the 
acceptance analysis 
Parameter ITT population (SD,%) Acceptance analysis 
population (SD,%) 
Number of patients 142 103 
Age (years) 76.7 (6.3) 76.6 (6.4) 
Gender (female, %) 76 (53.5) 67 (55.3) 
BMI (kg/m2) 28.4 (4.3) 28.4 (4.3) 
Morbidity (CIRS-G) 1.6 (0.4) 1.7 (0.4) 
No. of diagnoses 12.7 (5.7) 13.7 (6.1) 
No. of prescribed drugs 9.4 (3.1) 9.7 (3.3) 
No. of DRPs  7.3 (3.4) 7.1 (3.4) 
 
The results of the acceptance analysis are summarized in table 16 (detailed data in 
Appendix 8).  
 
 
 
 
 4. Results / p.80 
 
 
Tab. 16: Acceptance analysis per category 
Category accepted refused 
 
total 
start a drug 129 (51.8%) 120 (48.2%) 249 
stop a drug 133 (53.4%) 121 (47.6%) 254 
change a drug`s dose 104 (63.4%) 60 (36.6%) 164 
total 366 (54.9%) 301 (45.1%) 667 (100%) 
 
Reasons for refusal were the necessity of further information (18%), medical reasons 
(9%), budgetary reasons (5%) or special aspects in the patient’s treatment history 
(68%) that were unknown to the pharmacist. 
To find out whether certain influence factors might lead to a higher or lower 
frequency in accepting a suggested intervention, the 3 categories to start a drug 
treatment, to stop a drug treatment or to change a drug`s dose were tested versus 
the patient`s age, gender, education level, body mass index (BMI), morbidity (CIRS-
G), number of prescribed drugs, number of drug-related problems, number of patient-
reported adverse events, number of PRISCUS-PIMs, number of patient visits to the 
general practitioner per quarter (3 months), patient reported health (VAS), social 
support (FSozu14), cognitive impairment (MMSE), mobility (Tinetti test), everyday 
expertise (ADL and iADL) and adherence (Morisky score). The time effect of the 
acceptance over the trial period was assessed as well. The bivariate analyses 
demonstrated that interventions on stopping a prescribed drug were implemented 
significantly more often in patients with lower education level, cognitive impaired 
participants and in patients with good mobility. Suggestions to start a new drug 
treatment were implemented more frequently if the patient was female and less 
 4. Results / p.81 
 
 
frequently the more often the patient visited the general practitioner. Starting a new 
drug treatment based on the pharmacists’ suggestions was more frequent, the longer 
the patients stayed in the Medication Management process. General practitioners 
implemented more recommendations on changing a dose if the patient had a high 
BMI, manifold DRPs, good social support, performed well at everyday expertise and 
had cognitive impairment. General practitioners implemented fewer 
recommendations on dosage changes with increasing age of the patient and a good 
self-reported health status (p = 0.05). 
Influence factors gaining significance in the multivariate OLS regression analysis are 
shown in table 17. The multivariate model has shown no significant influence on the 
acceptance on stopping a prescribed drug.  
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Tab. 17: Influence factors on prescribers’ approval per 
category as analyzed by multivariate ordinary least squares 
(OLS) regression 
 Recommendations to 
Influence factors stop an existing 
drug        
Coefficient (SEE) 
start a new drug                            
 
Coefficient (SEE) 
change the dose 
of an existing drug 
Coefficient (SEE) 
Demographic variables 
Age  0.0199 (0.1289) -0.2303 (0.1428) -0.4506* (0.1915) 
Gender female 0.0719 (0.0993) 0.2062** (0.0605) 0.0164 (0.1183) 
Education level -0.0326 (0.0993) 0.0152 (0.0443) -0.0399 (0.0391) 
Nutrition 
BMI -0.0035 (0.0181) -0.0201 (0.0128) 0.0188 (0.0117) 
Morbidity  
CIRS-G -0.1133 (0.1084) 0.0886 (0.0932) -0.2032 (0.1485) 
Characteristics of medication 
No. of medication 
prescribed 
0.0169 (0.0166) 0.0138 (0.0186) -0.0116 (0.0184) 
No. of DRPs 0.0003 (0.0246) 0.0121 (0.0260) -0.0004 (0.0101) 
No. of patient-
reported ADEs 
0.0762 (0.0650) 0.0430 (0.1279) -0.0012 (0.0827) 
No. of PIM drugs -0.0098 (0.0502) 0.1113 (0.0747)    -0.0137 (0.1005) 
Physician-patient relationship 
No. of contacts per 
quarter 
-0.0123 (0.0080) -0.0299** (0.0049) -0.0022 (0.0058) 
Patient-reported health  
VAS 0.0044 (0.0028) -0.0002 (0.0036) -0.0030 (0.0019) 
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Social/family support  
FSozu K-14 0.0225 (0.0779) 0.0976 (0.0790) 0.1732** (0.0323) 
Cognitive impairment 
MMSE -0.0078 (0.0061) -0.0071 (0.0066) -0.0121* (0.0051) 
Mobility 
Tinetti Test -0.0186 (0.0107) -0.0153 (0.0100) -0.0014 (0.0110) 
Patient’s everyday expertise  
ADL -0.0057 (0.0053) 0.0086 (0.0083) -0.0176 (0.0102)  
iADL 0.0363 (0.0233) 0.0176 (0.0296) 0.0921** (0.0228) 
Patient-reported adherence 
Morisky-Score 0.0076 (0.0747) 0.0020 (0.0558) 0.0892 (0.0980) 
Time effect 0.0236 (0.0759) 0.1827 (0.0861) -0.0046 (0.0819) 
Adjusted R2 -0.025 0.14 0.33 
N 74 68 65 
Note:*p<0.05, **p<0.001 
Abbreviations: ADE: adverse drug event, ADL: activities of daily living, iADL: 
instrumental activities of daily living, CIRS-G: Cumulative Illness Rating Scale for 
Geriatrics, DRPs: drug-related problems, FSozu K-14: Fragebogen zur sozialen 
Unterstützung, short form 14, MMSE: Mini-Mental State Examination, PIM: potentially 
inadequate medication, SEE: standard error of the estimate (standard error of the 
regression), VAS: visual analogue scale 
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5. DISCUSSION 
 
5.1. DATA QUALITY AND LIMITATIONS 
 
The underlying data has several limitations. Involvement, implementation and 
feedback varied between the physicians as well as the MAI score baseline between 
the clusters. Some data was inconsistent, as not all analyzed parameters were 
covered by standard care. The stepped wedge study design led to a higher 
acceptance to participate but made statistics complicated. The patient interviews and 
the brown bag reviews were performed by the home-care specialists but are typically 
done by pharmacists. This limitation might on the other hand be regarded as a 
strength, as the patient interviews were performed comprehensively by the home 
care specialists. Visiting the patients at home might increase the completeness of the 
medication, whereas the patient could easily forget or hide drugs at a pharmacy visit. 
The reason for blinding the pharmacists was the funding program, which did not 
permit any personal advantage to a local pharmacist. Personal contact and patient 
counseling by the pharmacists might have led to a stronger study effect, as it is an 
important part of all pharmaceutical care activities. In this study the effects were 
limited on the cognitive skills of the pharmacist. The patient population of the 
WestGEM-study included multimorbid patients with a focus on cardiovascular 
diseases aged 65 or older with 5 or more drugs in use (polymedication). The 
inclusion criteria might already have narrowed down the eligible patients for a 
Medication Management and all results must be seen in this context. The effects of a 
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Medication Management are dependent on the acceptance of the pharmaceutical 
suggestions by general practitioners. 
Data on the analyses in LDL-cholesterol reduction was not sufficient. The study 
protocol should have emphasized the necessity of drawing quarterly LDL-cholesterol 
levels. 
The cut-off level of a reduction in the MAI score of 3.88 for a major benefit from a 
medication review cannot be seen as a definite number and might vary with the 
setting. The inclusion of several influence factors into the multivariate regression 
might have reduced the power of our sample. Furthermore, there were some 
interactions between variables weakening the influence, which was shown if 
compared to the bivariate models.  
The results of the acceptance of the collaborative Medication Management by the 
physicians derive from quantitative analyses only; a qualitative approach was only 
briefly analyzed here. All physicians had no previous experience with Medication 
Management. Some of the participating 12 physicians responded inertly on the 
feedback forms of the suggested interventions. Communication with the general 
practitioner was mainly based on the written SOAP form. A more intense 
communication could have helped to increase acceptance and to solve drug-related 
problems. 
The study was conducted as a regional project in two model regions in North Rhine-
Westphalia, Germany. The acceptance and effects of a collaborative Medication 
Management need to be repeated in different jurisdictions and settings.  
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5.2. EFFICACY OF THE MEDICATION MANAGEMENT 
 
5.2.1. MAI SCORE 
 
The reduction of the MAI score is significant in the three clusters as well as in the 
Mixed Model in the intervention group (-4.27, p < 0,001), hence the quality of drug 
therapy could be improved by the intervention of a Medication Management. This 
might be the first time that the effects of comprehensive Medication Management 
were demonstrated in a controlled study in a community setting in elderly multimorbid 
patients in Germany. The degree of MAI score reduction was in-line with other 
international studies [65]. It differs with the setting and the indication [54, 228]. A 
stronger effect can be expected with a higher MAI score baseline, characterizing a 
high potential for optimization [72]. The fact that the strongest effect correlated to the 
longest intervention time, indicates a time effect. During the study phase, it was 
noticed that physicians tended to implement medication changes stepwise over time. 
Careful and guarded changes seemed to be appropriate in patients with 
polymedication and high morbidity. Multiple changes could rather lead to adverse 
effects. Furthermore, all alterations must be communicated to the patients requiring 
effort and time. With regard to the German definition of a Medication Management as 
a longitudinal process, the findings support the thesis that patient care improves with 
time and is superior to individual Medication Reviews.  
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5.2.2. DRUG-RELATED PROBLEMS 
 
A significantly higher reduction in DRPs by -0,45 DRPs per patient could be found in 
the intervention group compared to the control group (p = 0,014). An initial rise in the 
number of DRPs could be explained by changes in the documentation of the 
physician. As the physician realized more drugs in patient`s medication and added 
them to his documentation, consequentially more DRPs could be registered. DRP 
reductions through pharmacists’ interventions could be shown in several other 
national and international studies [28, 71, 85, 229, 230]. Vinks et al. reported a 
reduction of the number of DRPs from 4.13 to 3.29 in the intervention group, which 
was a 0.69 higher reduction compared to the control group [28]. The community 
setting and the baseline number of taken drugs per patient (8.8) was similar to this 
study.  
 
5.2.3. LDL-CHOLESTEROL CONCENTRATIONS 
 
LDL-cholesterol is a relevant marker in cardiovascular diseases. A reduction might 
carry a patient benefit and reduce the risk for coronary heart disease, stroke and 
heart attack. The Medication Management led to a LDL-cholesterol reduction over 
time (t0t6) of -7.5 mg/dl from 114.1 mg/dl to 106.54 mg/dl (p = 0.012). However, the 
Mixed Model analysis did not reach significance. Interestingly, Machado et al. found 
in a review that all studies on pharmaceutical interventions in dyslipidemia came to a 
similar result. Lipid lowering was significant only in before-after analysis but not if 
compared to a control group [49]. Rating the clinical effect of the Medication 
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Management with these results is difficult. A large meta analysis of the Cholesterol 
Treatment Trialists’  Collaboration in 2010 comes to the conclusion that a LDL-
cholesterol reduction of 39 mg/dl results in a reduction of cardiovascular events of 
22% during a one-year period [139]. Results of another large analysis suggest that a 
LDL-cholesterol reduction by 10 mg/dl leads to a reduction of 6% of major 
cardiovascular events [140]. Baigent et al. found an 18 mg/dl LDL-cholesterol 
reduction equivalent to a 23% reduction in major cardiovascular events if sustained 
for 5 years [139]. Hence, the observed LDL-cholesterol reduction might as well be 
clinically meaningful and lead to a reduction in cardiovascular events in the studied 
population. The LDL-cholesterol levels in this population were far too high and did not 
meet current guideline targets, aiming at a LDL-cholesterol level of <70 mg/dl or 
<100 mg/dl in the elderly patient with high cardiovascular risk [138, 143]. As seen 
with the differences in the clusters, the awareness of LDL-cholesterol levels seems to 
differ among the participating 12 physicians. According to the guidelines and to 
evidence based medicine most of the study patients require an intense statin therapy, 
leading to a >50% reduction in LDL-cholesterol. The average level of 106.54 mg/dl 
after the Medication Management should be reduced further to meet at least the 
moderate geriatric goals of the ACC/AHA and ESC guideline on dyslipidemia of <100 
mg/dl [143]. During the qualitative part of the study many general practitioners 
expressed their expectation that pharmacists should rather assist them in 
discontinuing drugs than in starting a new therapy with their provision of Medication 
Management. Even though this was not supported by the acceptance analysis of this 
study, general practitioners seemed quite reluctant to initiate statins. On the other 
hand, the reduction in LDL-cholesterol levels in the analyzed 92 patients indicates 
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that some general practitioners responded well to the pharmaceutical suggestions 
and might not have been aware of the therapeutic requirement at routine work before. 
 
5.3. PATIENT SELECTION 
 
In the search of parameters, that correlated to a major benefit from a Medication 
Management and can be obtained easily by health care professionals, patient age, 
gender, eGFR, CIRS-G severity index, number of diagnoses, number of health care 
providers and the number of visits to the general practitioner during the last 6 months 
were not identified as covariates. These parameters should hence not be considered 
as patient selection criteria for a Medication Management. The results were quite 
surprising as multimorbidity and kidney function were regarded as potential risk 
factors for DRPs in a recent qualitative study by Kaufmann et al. and thus could be 
expected to have a correlation to the outcome of a medication review [231]. In a 
study by Green et al. the number of prescribing physicians was described as an 
independent risk factor for adverse drug events and was expected to be a risk factor 
for DRPs as well [232].  
Among the parameters that were initially available from the medical record or the 
laboratory data or that were obtainable by a patient interview, the number of drugs in 
use and a high discrepancy between drugs prescribed compared to the drugs 
actually taken at home could be identified as determining factors for having a special 
benefit from a Medication Management. Especially the number of drugs in use could 
serve as a valid and easily accessible criterion in selecting patients for a Medication 
Review. The HARM study identified polymedication of 5 or more drugs as a reason 
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for potentially preventable medication-related hospital admissions, supporting the 
findings presented here [233].  
Medication Reconciliation, which is usually a first step at Medication Management, 
could be useful for patient selection as well since a high discrepancy could be 
another decision criterion to initiate pharmaceutical patient care. Further analyses on 
parameters that are obtained later in Medication Management demonstrated a major 
benefit if the quality of medication was very low at baseline (as indicated by a high 
baseline MAI score) or if patients received longitudinal care with repeated Medication 
Reviews. Unfortunately, the calculation of the MAI score is very time consuming, 
might be regarded as a Medication Management itself and hence is not useful for 
identifying eligible patients in routine care. Otherwise, a MAI score of ≥24 could be 
suggested for the selection of eligible elderly patients with cardiovascular disease 
and similar inclusion criteria as in this study for a Medication Management. The effect 
of the Management on the quality of therapy increased significantly with the duration 
of performing patient care. A repeated Medication Review has proven to be 
reasonable in our study. The impact of the duration of the intervention with a 4-fold 
higher chance to benefit from a Medication Management after 3 additional months 
and a 4.7-fold higher chance after 6 months is profound. Future Medication 
Managements should emphasize the aspects of longitudinal patient care with 
repeated rather than with confined pharmaceutical services. These findings are in 
contrast to a study of Chinthammit et al. which favors shorter and less 
comprehensive reviews regarding the cost-effectiveness of a Medication 
Management [234]. 
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Some results of the analyses seem quite obvious but needed to be evaluated. It 
could be expected that patients with more drugs in use, a lower quality of therapy 
and a longitudinal care experience a larger benefit from the Medication Management. 
Furthermore, the results demonstrate that age and morbidity alone are no significant 
risk factors in the medication process. 
 
5.4. MEDICATION RECONCILIATION RESULTS 
 
The high deviation between the prescribed medicine and the intake at home was a 
surprising result of this study, with high discrepancies in virtually all regarded patients. 
The majority of discrepancies was related to clinically relevant prescription drugs and 
not limited to over-the-counter drugs. Medication Reconciliation clearly contributed to 
the findings in the Medication Management. Even though only descriptive research 
was done in Medication Reconciliation here, it is obvious that several high-risk 
medications were taken by the patients but were not documented and most likely 
unknown to the prescriber. There is no doubt that a medication with blood-pressure 
lowering drugs or anticoagulation drugs leads to a tremendous risk if it is not covered 
by a comprehensive care plan. With the upcoming obligation to provide a medication 
plan for patients from October 2016 on, a step towards reducing medication risks is 
done in Germany. According to the study results, the number of deviations was 
clearly related to the benefit of the Medication Management, indicating the need to 
revise therapy in these patients. The study advocates an interprofessional Medication 
Reconciliation.  
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5.5. ACCEPTANCE ANALYSIS 
 
Acceptance of the collaboration is a crucial aspect in Medication Management as 
many intervention need to be approved in order to reach the patient [235]. As 1082 
(63.5%) of 1705 suggestions for interventions to optimize the therapy at the 
Medication Management were rated by the general practitioner, a lot of data could be 
analyzed. The missing feedback on 36.5 % of the suggestions was caused by a 
minority of general practitioners, who responded inertly. The majority of 10 general 
practitioners cooperated fairly well. A feedback on almost two third of the questions 
(63.5%) demonstrates profound commitment of the general practitioners to the study. 
The in-depth analysis showed that about half of the suggestions of the pharmacists 
to stop a drug (53.4%) were accepted by the general practitioner. During the study 
some general practitioners expressed their expectation that more drugs should be 
discontinued and pharmacists should focus on a reduction of the number of drugs 
rather than on optimizing the therapy. Hence a high acceptance to stop a drug 
treatment could be expected. Some suggestions to discontinue a therapy might have 
been processed stepwise, as the general practitioners hesitated to implement too 
many recommendations at once. Benzodiazepines, zopiclone and zolpidem however 
were frequently suggested for discontinuation but hard for the general practitioner to 
realize, as the patient might have been addicted to the drug. In this context it is rather 
unexpected that more than half (51.8%) of the interventions by the pharmacists to 
start a drug treatment were accepted and processed by the general practitioners as 
well, indicating, that general practitioners followed the recommendations to start and 
to stop a drug treatment to a similar extent. Willingness to accept recommendations 
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on new drugs based on the pharmacist’s suggestions showed a high level of 
collaboration and trust between the professions, which exceeded the expectations, 
as some general practitioners seemed rather skeptical about the effects. Some 
doubtful general practitioners on the other hand were deeply involved in the study 
and reflected their former regimens even more than others. Another group of general 
practitioners uttered that they respected the suggestions in optimizing 
pharmacotherapy without any emotional restrictions. They felt safe with another 
profession revising the therapy and followed most advices, according to their own 
statements. 
General practitioners followed the suggestions to change a dose by almost two third 
(63.4%) and thus to an even higher extent than to start or stop a drug treatment. 
Optimizing a dose might be less effort and be more easy to communicate to the 
patient. The need to change a dose is sometimes overseen in daily practice and 
might be accepted well, as pharmacists frequently supported their suggestion by a 
calculation of the eGFR, by laboratory data or by vital signs. The low mean baseline 
eGFR of 55 ml/min, with 19% of the patients showing a eGFR of even 40 ml/min or 
below, indicates that in elderly patients with polymedication there is a clear need to 
revise drug dosages. Typical drugs that were adjusted to the renal function were 
statins, spironolactone and angiotensin-converting enzyme (ACE) inhibitors. Vital 
signs that were taken into account most frequently were the blood pressure, to adjust 
an antihypertensive regimen, and the pulse rate, to adjust the dose of beta-blocking 
agents. Typical laboratory data that led to changes in a drug’s dose were uric acid, to 
change the dose of allopurinol, LDL-cholesterol to change the dose of a statin and 
potassium, to change dosages of NSAIDs, ACE inhibitors/ARBs, thiazides, loop 
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diuretics and inhalative β2-agonists. Serum creatinine was compulsory for the 
pharmacists to calculate the eGFR.  
Compared to international studies, the acceptance of interventions in this work was 
quite high. In a study in France in outpatients with renal impairment by Pourrat et al. 
about one third of the interprofessional recommendations were accepted [236]. A 
recent study of Chau et al. in the Netherlands, which was done in a comparable 
setting and with similar patient characteristics (mean age of 78 years, about 9 drugs 
in use), found 46.6% of the suggested interventions on stopping a drug treatment, 
43.3% on adjusting a drug’s dose and 36.3% on adding a new drug accepted [197]. 
The lower implementation rate in this Dutch study is surprising as the 
interprofessional collaboration in the Netherlands is well established, whereas there 
is no implemented communication between pharmacists and physicians in Germany. 
The implementation rate might on the other hand increase with the clinical expertise 
of the pharmacists. As a very large group of pharmacists contributed to the results in 
the Dutch study, there might have been some heterogeneity in the clinical skills of the 
participating pharmacists, which comes closer to a real-life setting. In a clinical 
setting and with close collaboration on the ward, higher acceptance rates of up to 
92% could be reached [27, 198, 237].  
The results of this study on the acceptance rate in an outpatient setting however, can 
send out an encouraging signal on interprofessional collaboration in Germany. 
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5.6. MEDICATION SAFETY IN THE STUDIED POPULATION 
 
With a mean of 11 detected DRPs per patient on the general practitioner’s level and 
additional DRPs at patient side, the study population was very susceptible to 
medication risks. In study meetings with the physicians, the relevance and severity of 
the reported DRPs was intensively discussed. Some DRPs, as the prescription of 2 
beta-blocking agents in the same patient, were very obvious and helped to create 
susceptibility on the intervention. Obvious examples might have increased 
awareness of the potential risks of the medication in the studied population and 
furthermore in routine care. Reasons for hospitalization were not analyzed in our 
study so far. Hohl et al. found that 10% of all emergency room visits were drug- 
related [238]. A review by Patel et al. related 28% of all emergency department visits 
to DRPs with 70% of them being preventable [239]. Based on these findings, the 
relevance of medication safety can be assumed for the studied population. 
1705 suggestions on optimizing the therapy were suggested to the physicians. Even 
though some of them could not be impliemented for several good reasons, a clear 
potential for improvement on medication safety (Arzneimitteltherapiesicherheit, 
AMTS) could be seen in the elderly, multimorbid patients with polymedication. The 
high acceptance of recommended interventions by the physicians proves that a 
collaborative approach improving drug therapy is highly desired and could lead to a 
patient benefit. 
 
 
 5. Discussion / p.96 
 
 
5.6.1. DRUG-DRUG INTERACTIONS 
 
Drug-drug interactions were addressed as one step in the pharmaceutical 
assessment. A prevalent interaction was the combination of multiple drugs affecting 
potassium levels and kidney function, namely thiazides, NSAIDs, loop-diuretics and 
ACE inhibitors/ARBs. For estimating the severity of relevant interactions, multiple 
factors played a much larger role than pairwise interactions, which usually were of 
lower relevance in these patients. A frequently reported interaction was the 
combination of proton-pump inhibitors (PPI) with other magnesium-excretion 
enhancing drugs like thiazides or loop diuretics. Relevance was granted in this 
situation only if the patient reported a history of lower leg cramps. Cytochrom P-450 
related interactions were detected frequently but were rated with low relevance in 
many cases. Amlodipine and simvastatin are an example of a more frequent CYP 
3A4 interaction and led to a suggested dose reduction of the statin. Physicians were 
mainly grateful for notifications on drug-drug interactions, even though the relevance 
was discussed intensively. On the pharmacists’ side, it was soon found out that the 
drug-drug interaction detecting tools (e.g. the ABDA database) were helpful only as a 
first screening tool but frequently did not reflect the clinical severity or relevance of 
the interaction sufficiently. Individual patient parameters and multiple interactions as 
well as the drug history played a distinguished role in estimating the severity of an 
interaction. The contribution of drug-drug interaction detection tools to medication 
safety hence seemed to be limited in elderly multimorbid patients and a patient-
individual approach should be preferred. These findings were described by other 
studies before. Van Roon et al. and Bergk et al. came to the result that in general 
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practice several interactions require no further action or are easily manageable [240, 
241]. 
 
5.6.2. UNDER- AND OVERTREATMENT 
 
Part of each particular Medication Management is the determination of therapeutic 
goals, wherever possible in accordance with current guidelines. In case of interfering 
recommendations by guidelines, a weighting of the best approach was done in this 
study. An example for the necessity to weigh guideline recommendations was the 
prescription of a beta-blocking agent in coronary heart disease with a concomitant 
asthma therapy, where beta-sympathomimetic agents are recommended [242]. 
 A prevalent conflict with guidelines was the undersupply of patients with certain 
drugs, specifically recommended in their disease state. In coronary heart disease the 
guidelines recommend the patient to be supplied with a short acting nitrate to have a 
fast relieve on symptoms [243]. Prescription of short acting nitrates was, however, 
hardly seen in the study patients and was frequently declined, probably due to the 
drug costs. As demonstrated before, LDL-cholesterol was addressed by many 
participating physicians inertly, leading to an undersupply in statins, which is in-line 
with international data [244]. Short-acting betasympathomimetic agents (SABA) are 
recommended to all patients with an asthma therapy by the guidelines but were not 
prescribed to some of the study patients for unknown reasons [245]. In summary, an 
underprescribing was noticed mainly in dyslipidemia, coronary heart disease and 
pain therapy.  
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On the other hand, some regimens were seen that are not consistent with current 
guidelines. Prescription of systemic steroids in asthma and COPD didn`t seem to be 
appropriate for the majority of patients seen here. Drugs from the PRISCUS list are a 
burden that cannot be avoided in some cases. Amitriptylin, in contrast, was still 
commonly prescribed but could easily be substituted. Prescription of too many drugs 
or excessive doses was seen frequently in antihypertensive and antidiabetic therapy 
regimens. In hypertension severe lowering of the blood pressure doesn`t carry any 
benefit and increases the risk of falling. The current European guideline for 
hypertension reflects these findings with higher blood pressure goals [246]. In 
antidiabetic therapy intensive lowering of blood glucose and HbA1c levels carries the 
risk of hypoglycemia [247].  
 
5.6.3. PATIENT GOALS 
 
Patient goals in the studied population were related mainly to a better pain-
management, to pruritus reduction and a higher resilience. Patient goals were 
obtained by the home care specialists as a part of the home care and pharmaceutical 
assessment and seemed to differ from the patient goals the physicians noted. An 
explanation for this discrepancy could be the different setting. In a physician’s 
practice the attention of the patient might be drawn to other, acute problems and the 
available time with the physician is limited. The assessment of the home care 
specialist, in contrast, was done without urgency and at home environment, 
furthermore the patient was implicitly assessed and asked for pain, excretion, vertigo 
and other aspects interfering with quality of life. Physicians were grateful for this 
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structured assessment, providing new information to them. In pain management and 
due to the high cardiovascular risk of the patients, NSAIDs were frequently 
suggested to the physician for discontinuation and acetaminophen or metamizol 
(despite the risk of agranulocytosis), or a combination of both was suggested as a 
replacement [248, 249]. For more severe pain a switch to opioids was the only 
approach left with a risk for dizziness and obstipation and hence probably causing a 
new prescription cascade [250]. As many patients reported severe pain in the 
assessment, pain medication was frequently suggested for alterations, 
underprescribing seemed to be prevalent. 
 
5.7. CONCLUSIONS 
 
Aspects of this elaborations were the effects of the Medication Management on the 
quality of drug therapy, the identification of risk groups, who might carry a major 
benefit from the intervention, an analysis of the efficacy at patient level and an 
assessment of the interprofessional collaboration.  
Significant effects could be shown for the reduction of the MAI score and DRPs, 
indicating an improve in the quality of drug therapy. LDL-cholesterol reduction could 
show trends but no significant improvements versus the control group. Further 
research with specifically designed studies is needed to demonstrate positive results. 
The analysis of eligible patient groups suggests that the number of drugs in use is a 
valid screening criterion. It is easily accessible and correlates to the outcomes of a 
Medication Management.  
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The acceptance of the recommendations is a measure of interprofessional 
collaboration, which is often the bottleneck in Medication Management. Health 
insurances might hesitate to implement Medication Management even if the right 
patients are selected and an efficacy is expected, if the structures in collaboration do 
not make the intervention likely to reach the patient. The acceptance rate was 
profound and could likely even be increased with direct physician-pharmacist 
communication, which was not a standard procedure in the approach here. A part of 
the medication was not documented and most probably unknown to the prescriber 
and could be taken into account by the interprofessional approach. 
With positive results in all elaborated domains, the efficacy of a Medication 
Management could be shown from different perspectives. Each aspect contributes to 
the patient outcomes and only by covering all aspects a Medication Management can 
be momentous to the patient and the society. The results of this study suggest that 
selecting eligible patients, performing a comprehensive Medication Management and 
collaborating interprofessionally leads to a patient benefit. 
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6. FUTURE PROSPECTS  
 
Summarizing the results of this thesis, it can be stated that the implementation of a 
Medication Management would contribute to patients’ health and medication safety in 
Germany. It would be suggested that future patient selection should mainly be 
depending on the number of drugs in use. In case of a high discrepancy between the 
prescribed and the used medication at the point of Medication Reconciliation, which 
is an indispensable component of a Medication Management according to the study 
results, additional attention should be paid to the patient. The cut-off of the number of 
systemic drugs in use could be adjusted to the estimated capacities of German 
pharmacies and physicians. In case of a certain discrepancy between the prescribed 
and the used drugs it would be meaningful to take further measures, i.e. a more 
intense type 3 Medication Review or a repeated follow-up. An increase in the efficacy 
of a Medication Management can be expected with growing interprofessional trust. 
Results of this study support a longitudinal patient care, future implementations 
should focus on continuous pharmaceutical services.  
To ensure a high level of collaboration, standard procedures should be developed, 
evaluated and implicated into daily routine. For a timesaving communication, special 
forms can be developed and certain times could be reserved for a case conference. 
As pharmacotherapy is just a small facet in patient care in daily medical practice, 
there is a great potential for interprofessional cooperation. With regard of the study 
results it could be assessed whether blood pressure and pulse rate, serum creatinine, 
LDL-cholesterol, uric acid and potassium should regularly be available to the 
pharmacist in order to facilitate the Medication Management. With regard to a more 
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effective interprofessional collaboration, efforts should be done to overcome existing 
barriers. New prospects of professional development  should be explored, as it is 
done in different jurisdictions and settings [50, 251]. Findings of this work are in 
accordance with the outcomes of Medication Management seen in other countries 
and support the thesis that there is a strong potential for patient-oriented 
pharmaceutical and interprofessional services in Germany.  
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7. SUMMARY 
 
Medication Review and Medication Management are new pharmaceutical care 
services with a strong potential to contribute to patients’ health care outcomes. The 
aim of this work was to evaluate an interprofessional, collaborative Medication 
Management in an outpatient setting in Germany. Objectives were to assess the 
efficacy of the intervention, to identify risk groups, who might carry a higher benefit 
from a Medication Management, to assess the results of the Medication 
Reconciliation process and to examine the acceptance of the collaborative 
Medication Management.  
165 elderly multimorbid patients from 12 primary care practices were included in this 
cluster-randomized controlled study, following a stepped wedge design. A 
comprehensive Medication Review was performed twice and interprofessional action 
was undertaken, leading to prospective data on 142 patients and covering a 15 
months’ span of life. 
With a greater reduction in the MAI score of 4.27 points (p < 0.001) in the 
intervention group, the efficacy of a Medication Management in improving the quality 
of drug therapy was demonstrated. DRPs were reduced significantly, supporting this 
result. The efficacy in terms of the reduction of LDL-cholesterol concentrations 
showed significance in the before-after analysis (p = 0.012). However, in a Mixed 
Model the effect of the intervention was not significant.  
The results further suggest the number of drugs in use (p=0.001) and the number of 
discrepancies between prescribed and used drugs (p=0.014) as patient selection 
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criteria for a Medication Management. The baseline MAI score (p<0.001) and the 
length of the intervention (p=0.006) correlated with positive outcomes as well but are 
not feasible for patient selection.  
Medication Reconciliation revealed that the majority of drugs, which were not 
documented by the prescriber, were prescription drugs with clinically significant 
effects and risks. Therefore, an individual medication plan is highly desired to 
increase patient safety.  
The interprofessional acceptance of the study with 54.9% of the recommendations 
being implemented, shows an effective collaboration between physicians and 
pharmacists within the Medication Management process.  
The demonstrated efficacy and a high interprofessional acceptance support the 
implementation of a Medication Management into German health care.  
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Appendix 4: Brown bag review and patient assessment form 
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ID LDL1 LDL2 LDL3 LDL4 LDL5 LDL6 LDL7 Zentr. Interv. ITT 
103 148 148 70 97 70 43 48 1 1.7.2014 1 
105 117 117 121 121 102 102 113 1 1.7.2014 1 
111 86 86 86 77 66 75 75 1 1.7.2014 1 
112 170 170 170 115 140 77 88 1 1.7.2014 1 
113 91 91 91 86 86 86 86 1 1.7.2014 1 
118 117 117 117 138 148 134 134 1 1.7.2014 1 
124 77 77 77 85 69 85 85 1 1.7.2014 1 
133 72 72 71 68 63 69 55 1 1.7.2014 1 
137 125 125 110 114 114 116 112 1 1.7.2014 1 
140 107 107 106 117 110 137 134 1 1.7.2014 1 
207 159 159 112 117 83 118 109 2 1.1.2014 1 
211 100 100 100 115 119 130 101 2 1.1.2014 1 
213 85 85 91 81 62 60 57 2 1.1.2014 1 
216 101 98 104 64 62 62 60 2 1.1.2014 1 
217 102 102 102 98 98 102 102 2 1.1.2014 1 
219 119 119 111 128 116 122 121 2 1.1.2014 1 
220 91 91 91 77 83 87 66 2 1.1.2014 1 
221 107 107 107 107 107 103 118 2 1.1.2014 1 
222 80 80 72 83 87 92 76 2 1.1.2014 1 
225 175 175 175 191 191 187 179 2 1.1.2014 1 
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ID LDL1 LDL2 LDL3 LDL4 LDL5 LDL6 LDL7 Zentr. Interv. ITT 
231 144 144 144 144 144 137 139 2 1.1.2014 1 
233 77 55 35 35 45 49 54 2 1.1.2014 1 
234 110 110 113 113 77 77 77 2 1.1.2014 1 
236 90 90 90 90 78 78 97 2 1.1.2014 1 
304 188 188 188 188 188 183 183 3 1.4.2014 1 
333 115 115 115 115 115 115 115 3 1.4.2014 1 
334 82 82 82 82 82 82 82 3 1.4.2014 1 
401 66 66 74 74 66 66 66 4 1.4.2014 1 
412 117 117 117 117 117 117 117 4 1.4.2014 1 
414 100 100 115 115 115 115 115 4 1.4.2014 1 
416 129 129 129 129 129 129 129 4 1.4.2014 1 
501 104 104 108 92 99 99 105 5 1.1.2014 1 
503 74 74 74 99 99 99 99 5 1.1.2014 1 
504 144 144 130 108 111 152 147 5 1.1.2014 1 
505 99 99 115 84 94 94 107 5 1.1.2014 1 
506 90 90 90 106 106 106 106 5 1.1.2014 1 
511 82 82 82 101 86 86 86 5 1.1.2014 1 
512 219 219 219 240 240 239 252 5 1.1.2014 1 
517 86 86 86 106 106 106 106 5 1.1.2014 1 
523 104 104 104 104 100 92 92 5 1.1.2014 1 
529 66 66 80 77 87 94 89 5 1.1.2014 1 
530 77 77 50 50 57 57 62 5 1.1.2014 1 
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ID LDL1 LDL2 LDL3 LDL4 LDL5 LDL6 LDL7 Zentr. Interv. ITT 
533 104 104 118 118 118 118 118 5 1.1.2014 1 
535 181 181 171 171 171 171 178 5 1.1.2014 1 
539 126 126 96 86 86 86 86 5 1.1.2014 1 
540 82 82 82 82 121 121 138 5 1.1.2014 1 
602 158 158 133 117 96 103 116 6 1.7.2014 1 
619 187 187 187 176 176 176 176 6 1.7.2014 1 
622 103 103 93 126 109 101 94 6 1.7.2014 1 
625 141 141 141 141 141 141 141 6 1.7.2014 1 
626 65 65 66 62 59 65 51 6 1.7.2014 1 
629 80 80 91 71 53 73 73 6 1.7.2014 1 
630 165 165 165 165 165 165 165 6 1.7.2014 1 
636 65 65 65 79 79 64 81 6 1.7.2014 1 
637 88 88 88 62 66 66 66 6 1.7.2014 1 
639 134 116 116 101 100 115 112 6 1.7.2014 1 
705 94 94 94 86 86 103 92 7 1.7.2014 1 
707 134 134 127 127 100 101 114 7 1.7.2014 1 
712 194 194 194 194 78 78 87 7 1.7.2014 1 
716 107 107 120 172 157 136 161 7 1.7.2014 1 
718 78 78 78 68 68 78 81 7 1.7.2014 1 
719 150 150 150 150 150 150 150 7 1.7.2014 1 
720 107 107 98 98 98 98 98 7 1.7.2014 1 
811 171 171 171 171 171 171 171 8 1.4.2014 1 
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ID LDL1 LDL2 LDL3 LDL4 LDL5 LDL6 LDL7 Zentr. Interv. ITT 
902 97 97 97 97 113 113 113 9 1.1.2014 1 
906 95 87 96 72 149 121 104 9 1.1.2014 1 
908 125 125 127 127 141 141 141 9 1.1.2014 1 
909 121 121 121 93 93 66 66 9 1.1.2014 1 
910 103 103 86 86 105 98 74 9 1.1.2014 1 
911 137 137 137 97 97 92 103 9 1.1.2014 1 
912 137 137 163 150 142 147 147 9 1.1.2014 1 
917 141 141 146 118 142 125 125 9 1.1.2014 1 
919 77 77 119 113 89 74 96 9 1.1.2014 1 
920 142 142 136 1,8 1,8 137 137 9 1.1.2014 1 
921 249 249 249 222 166 166 166 9 1.1.2014 1 
1102 140 140 140 118 122 122 136 11 1.1.2014 1 
1105 140 140 140 117 97 109 109 11 1.1.2014 1 
1112 81 81 78 78 78 70 94 11 1.1.2014 1 
1115 92 92 92 92 125 100 100 11 1.1.2014 1 
1116 78 78 78 53 53 69 57 11 1.1.2014 1 
1117 96 96 96 107 107 107 107 11 1.1.2014 1 
1123 112 112 112 112 90 90 73 11 1.1.2014 1 
1131 99 99 99 120 125 130 130 11 1.1.2014 1 
1133 117 117 117 100 100 79 79 11 1.1.2014 1 
1134 106 106 106 106 106 106 106 11 1.1.2014 1 
1135 120 120 113 113 106 106 113 11 1.1.2014 1 
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ID LDL1 LDL2 LDL3 LDL4 LDL5 LDL6 LDL7 Zentr. Interv. ITT 
1203 84 84 103 103 103 149 109 12 1.7.2014 1 
1206 125 125 125 125 125 101 109 12 1.7.2014 1 
1208 60 60 60 60 60 60 55 12 1.7.2014 1 
1211 86 86 81 92 92 92 98 12 1.7.2014 1 
1409 138 138 138 138 62 62 62 14 1.4.2014 1 
1419 92 92 100 100 100 100 100 14 1.4.2014 1 
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Appendix 7: Individual patient data on suggested and rated 
interventions 
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Patient-ID 
  
  
suggested 
interventions 
by pharmacist 
rated 
interventions 
by GP 
0103 12 0 
0105 17 0 
0111 9 0 
0112 14 0 
0113 9 0 
0118 13 0 
0124 6 0 
0133 18 0 
0137 14 0 
0140 9 0 
0207 19 13 
0208 12 4 
0210 13 9 
0211 10 10 
0213 10 10 
0216 13 11 
0217 9 7 
0219 18 14 
0220 9 8 
0221 9 8 
0222 9 9 
0225 14 9 
Patient-ID 
  
  
suggested 
interventions 
by pharmacist 
rated 
interventions 
by GP 
0227 16 13 
0231 10 10 
0233 12 12 
0234 14 14 
0236 11 9 
0238 18 10 
0304 23 12 
0305 9 9 
0309 16 15 
0333 12 12 
0334 8 8 
0401 11 0 
0404 14 14 
0410 12 0 
0412 11 0 
0414 13 0 
0416 16 4 
0417 7 0 
0501 27 27 
0503 10 5 
0504 12 12 
0505 16 16 
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Patient-ID 
  
  
suggested 
interventions 
by pharmacist 
rated 
interventions 
by GP 
0506 14 10 
0511 17 15 
0512 13 12 
0517 14 14 
0523 15 12 
0529 10 10 
0530 17 7 
0535 13 12 
0539 15 15 
0540 11 3 
0601 8 8 
0602 10 0 
0604 10 0 
0611 10 0 
0612 13 0 
0614 12 0 
0617 12 0 
0619 12 0 
0620 16 0 
0622 12 0 
0625 10 5 
0626 16 3 
Patient-ID 
  
  
suggested 
interventions 
by pharmacist 
rated 
interventions 
by GP 
0628 13 0 
0629 3 0 
0630 15 4 
0632 8 2 
0636 14 14 
0637 16 0 
0639 11 2 
0705 11 10 
0707 8 8 
0708 16 16 
0712 13 13 
0713 6 6 
0716 10 10 
0718 11 11 
0719 15 15 
0720 12 12 
0801 10 10 
0811 18 17 
0815 5 5 
0818 13 13 
0820 15 15 
0823 10 10 
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Patient-ID 
  
  
suggested 
interventions 
by pharmacist 
rated 
interventions 
by GP 
0824 10 10 
0828 17 16 
0830 5 5 
0832 12 12 
0840 10 1 
0845 20 15 
0902 7 7 
0904 9 9 
0906 14 14 
0908 14 14 
0909 9 9 
0910 18 18 
0911 7 7 
0912 16 16 
0917 15 13 
0919 14 14 
0920 14 11 
0921 19 19 
0940 18 18 
1102 15 15 
01102 12 0 
1105 10 10 
Patient-ID 
  
  
suggested 
interventions 
by pharmacist 
rated 
interventions 
by GP 
1106 16 16 
1112 8 8 
1114 17 17 
1115 16 16 
1116 10 10 
1117 7 7 
1122 18 18 
1123 13 12 
1127 13 13 
1131 14 14 
1132 16 16 
1133 14 14 
1134 13 13 
1135 15 15 
1203 13 0 
1206 16 0 
1208 7 0 
1211 10 0 
1401 9 6 
1402 13 6 
1409 13 8 
1418 5 2 
 Appendices / p.172 
 
 
Patient-ID 
  
  
suggested 
interventions 
by pharmacist 
rated 
interventions 
by GP 
1419 19 3 
1423 16 6 
1424 10 3 
1427 12 3 
1431 12 3 
1438 20 12 
1440 6 3 
  
    
  total 1753 1130 
  
    mean mean 
  12,6 8,1 
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Appendix 8: Response form for the general practitioner on 
acceptance of the suggested interventions 
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Appendix 9: Individual patient data on the acceptance of the 
GPs 
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Patient-
ID ‘stop a drug’ processed? ‘start a drug’ processed ‘change in dose’ processed? 
  yes no yes no yes no 
0103 0 0 0 0 0 0 
0105 0 0 0 0 0 0 
0111 0 0 0 0 0 0 
0112 0 0 0 0 0 0 
0113 0 0 0 0 0 0 
0118 0 0 0 0 0 0 
0124 0 0 0 0 0 0 
0133 0 0 0 0 0 0 
0137 0 0 0 0 0 0 
0140 0 0 0 0 0 0 
0207 1 1 2 1 
  0208 0 0 0 0 0 0 
0210 1 2 
  
1 1 
0211 3 
 
5 
  
1 
0213 2 1 1 3 2 1 
0216 1 1 1 
 
2 
 0217 
 
1 
  
3 
 0219 3 3 
 
1 2 1 
0220 
 
2 1 1 
 
1 
0221 
     
1 
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Patient-
ID ‘stop a drug’ processed? ‘start a drug’ processed ‘change in dose’ processed? 
0222 
 
2 
 
1 
 
2 
0225 3 1 3 1 
  0227 1 3 3 
  
1 
0231 1 2 
 
3 1 
 0233 1 1 1 1 1 
 0234 1 
   
3 1 
0236 1 
 
2 
 
3 
 0238 1 2 4 3 
  0304 
 
4 4 1 1 1 
0305 
  
3 
 
1 
 0309 2 1 4 
   0333 
 
1 4 2 
 
1 
0334 1 
 
3 
 
2 
 0401 0 0 0 0 0 0 
0404 5 1 3 1 1 
 0410 0 0 0 0 0 0 
0412 0 0 0 0 0 0 
0414 0 0 0 0 0 0 
0416 2 
   
2 
 0417 0 0 0 0 0 0 
0501 1 3 
  
1 
 0503 2 1 
  
1 
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Patient-
ID ‘stop a drug’ processed? ‘start a drug’ processed ‘change in dose’ processed? 
0504 1 1 2 2 2 1 
0505 1 1 
 
1 1 
 0506 3 1 3 
 
2 
 0511 3 2 1 
 
2 
 0512 1 1 1 1 
  0517 
 
1 2 
 
1 
 0523 1 2 1 3 1 
 0529 
    
1 
 0530 1 
     0535 
  
1 
   0539 1 1 
    0540 1 1 2 
 
2 
 0601 1 1 1 1 
  0602 
  
1 
   0604 0 0 0 0 0 0 
0611 0 0 0 0 0 0 
0612 0 0 0 0 0 0 
0614 0 0 0 0 0 0 
0617 0 0 0 0 0 0 
0619 0 0 0 0 0 0 
0620 0 0 0 0 0 0 
0622 
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Patient-
ID ‘stop a drug’ processed? ‘start a drug’ processed ‘change in dose’ processed? 
0625 2 
 
1 
  
1 
0626 1 
 
1 
   0628 0 0 0 0 0 0 
0629 0 0 0 0 0 0 
0630 1 
 
1 
   0632 0 0 0 0 0 0 
0636 
 
2 
 
1 1 2 
0637 0 0 0 0 0 0 
0639 1 
     0705 
 
1 
 
5 1 
 0707 1 1 1 
 
3 1 
0708 
 
4 3 4 1 
 0712 1 
  
4 
 
2 
0713 
 
1 
 
3 
 
1 
0716 1 5 1 
  
1 
0718 
 
1 
 
4 3 
 0719 2 
 
1 2 4 2 
0720 1 1 1 3 
  0801 2 
 
6 
   0811 6 
 
8 
 
2 
 0815 
    
1 1 
0818 3 
 
1 
 
1 
 
 Appendices / p.180 
 
 
Patient-
ID ‘stop a drug’ processed? ‘start a drug’ processed ‘change in dose’ processed? 
0820 
 
4 2 
 
3 3 
0823 1 
 
1 1 
 
1 
0824 
 
4 1 2 1 
 0828 4 4 3 1 2 2 
0830 2 
     0832 2 1 
 
2 
 
3 
0840 1 0 1 0 0 0 
0845 3 3 5 1 
 
2 
0902 1 1 
 
1 2 1 
0904 1 1 1 3 
 
1 
0906 1 
   
3 
 0908 1 3 1 4 
  0909 
 
2 
 
2 
 
3 
0910 
 
3 
 
1 2 
 0911 
 
2 
 
1 1 
 0912 3 1 
 
2 3 1 
0917 1 2 1 4 
 
1 
0919 3 
 
1 2 2 2 
0920 2 
 
3 1 2 1 
0921 2 4 
 
5 
 
2 
0940 2 5 
 
5 2 2 
1102 1 2 
 
2 3 
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Patient-
ID ‘stop a drug’ processed? ‘start a drug’ processed ‘change in dose’ processed? 
01102 0 0 0 0 0 0 
1105 1 
 
1 1 2 1 
1106 2 3 2 3 
  1112 
    
1 1 
1114 1 1 1 1 6 1 
1115 2 3 4 1 1 2 
1116 1 
 
2 1 1 
 1117 
  
4 
   1122 3 1 2 2 3 
 1123 2 2 2 4 
 
1 
1127 1 4 1 2 2 
 1131 6 1 1 
 
2 
 1132 1 2 
 
4 1 
 1133 4 1 2 3 1 
 1134 2 1 2 2 1 1 
1135 1 1 
 
4 
 
1 
1203 0 0 0 0 0 0 
1206 0 0 0 0 0 0 
1208 0 0 0 0 0 0 
1211 0 0 0 0 0 0 
1401 1 
 
1 
 
2 
 1402 1 
   
2 2 
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Patient-
ID ‘stop a drug’ processed? ‘start a drug’ processed ‘change in dose’ processed? 
1409 3 2 
 
1 1 
 1418 1 
    
1 
1419 
    
1 1 
1423 
 
3 
  
1 
 1424 1 
   
1 
 1427 
 
1 
   
1 
1431 
   
2 1 
 1438 3 2 2 4 1 
 1440 
    
1 1 
 
  
‘stop a drug’ 
processed? 
 
‘start a drug’ 
processed 
 
‘change in 
dose’ 
processed? 
 total 137 131 131 128 114 63 
  yes no yes no yes no 
  total number 704 
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